DEDICATION

To our families—Eva, Sara, Matthew and Isabella; Kevin, Sarah, Christopher, Jennifer, and Katherine; Melissa, Dan, Gabi, Gretta, Grant, Geoff, Mary, Cotes, and Anderson—and to our many colleagues and friends, who have inspired and supported us throughout the years.
Contents

Contributors
Conflicts of Interest
Preface
Important Notice (Please Read)

1. Introduction / 1
DOUGLAS D. RICHMAN, RICHARD J. WHITLEY, AND FREDERICK G. HAYDEN

Section I

VIRAL SYNDROMES AND GENERAL PRINCIPLES

2. Respiratory Infections / 9
JOHN J. TREANOR

3. Viral Infections of the Central Nervous System / 31
KEVIN A. CASSADY AND RICHARD J. WHITLEY

4. Gastrointestinal Syndromes / 47
EYAL LESHEM AND UMESH D. PARASHAR

5. Viral Hepatitis / 61
ZINA S. VALAYDON, STEPHEN A. LOCARNINI, AND ALEXANDER J.V. THOMPSON

6. Viral Infections in Organ Transplant Recipients / 75
JOHN A. ZAIA

7. Viral Heart Disease / 99
BRUCE M. McMANUS, MICHAEL SEIDMAN, KARIN KLINTEL, AND HONGLIN LUO

8. Viral Diseases of the Skin / 115
ZEENA Y. NAWAS AND STEPHEN K. TYRING

9. Viral Hemorrhagic Fevers / 141
GAIL CARSON, MIKE BRAY, AND CATHY ROTH

10. Viral Disease of the Eye / 151
HOWARD M. NEWMAN

11. Antiretroviral Agents / 169
CHRISTINE J. KUBIN, BARBARA S. TAYLOR, AND SCOTT M. HAMMER

12. Antiherpesvirus Agents / 215
CLAIRE L. GORDON, CHRISTINE J. KUBIN, AND SCOTT M. HAMMER

13. Anti–Hepatitis Virus Agents / 239
MATTHEW L. SCHERER, CHELSEA SAMMONS, BRIAN NELSON, SCOTT M. HAMMER, AND ELIZABETH Verna

14. Antirespiratory Virus Agents / 271
MARCUS R. PEREIRA, BENJAMIN A. MIKO, MONICA MEHTA, AND SCOTT M. HAMMER

15. Diagnosis of Viral Infections / 291
GUY BOIVIN, TONY MAZZULLI, AND MARTIN PETRIC

16. Immune Responses to Viral Infection / 321
HENDRIK STREECK, TODD J. SUSCOVICH, AND GALIT ALTER

17. Immunization Against Viral Diseases / 351
JULIE E. LEDGERWOOD AND BARNEY S. GRAHAM

18. Chronic Fatigue and Postinfective Fatigue Syndromes / 371
ANDREW R. LLOYD

Section II

THE AGENTS

PART A: DNA VIRUSES

19. Poxxviruses / 387
STUART N. ISAACS AND R. MARK BULLER

20. Herpes Simplex Viruses / 415
RICHARD J. WHITLEY AND BERNARD ROIZMAN

21. Cercopithecine Herpesvirus 1 (B Virus) / 447
RICHARD J. WHITLEY
Contributors

CLAS AHLIN
Umeå University, Department of Clinical Microbiology
S-901 87 Umeå, Sweden

GÖRAN AKUSJÄRVI
Uppsala University
Uppsala 75123 Sweden

GALIT ALTER
Ragon Institute for MGH, MIT and Harvard
Cambridge, MA 02139

DANIELLE E. ANDERSON
Programme in Emerging Infectious Diseases
Duke-NUS Medical School,
8 College Road
Singapore 169857

JUANA ANGEL
Facultad de Medicina, Instituto de Genética Humana
Pontificia Universidad Javeriana
Bogotá, Colombia

CARLOS F. ARIAS
Instituto de Biotecnología/UNAM
Cuernavaca 62210, Mexico

ROBERT L. ATMAR
Baylor College of Medicine
Houston, TX 77030

ALAN D.T. BARRETT
University of Texas Medical Branch
Galveston, TX 77555

DANIEL G. BAUSCH
Tulane School of Public Health and Tropical Medicine
New Orleans, LA 70112

MARTIN BEER
Friedrich-Loeffler-Institut
Greifswald—Insel Riems 17493, Germany

GUY BOIVIN
CHU de Quebec-Laval University
Quebec City, QC, Canada G1V 4G2

WILLIAM BONNEZ
University of Rochester School of Medicine and Dentistry
Rochester, NY 21702

MIKE BRAY
National Institutes of Health
Bethesda, MD 20892

KEVIN E. BROWN
Public Health England, Virus Reference Department
London, NW9 5EQ, United Kingdom

ROBERTA L. BRUHN
Blood Systems Research Institute
San Francisco, CA 94118

R. MARK BULLER
Saint Louis University School of Medicine
St. Louis, MO 63104

GAIL CARSON
Nuffield Department of Medicine
University of Oxford
Oxford, United Kingdom

KEVIN A. CASSADY
Nationwide Children’s Hospital
Columbus, OH 43205

YUAN CHANG
University of Pittsburgh Cancer Institute
Pittsburgh, PA 15213

DANIEL S. CHERTOW
National Institutes of Health
Bethesda, MD 20892
ALESSIA CIANCIO
University of Torino, Department of Medical Sciences
Torino 10126, Italy

HARRY R. DALTON
Royal Cornwall Hospital
Department of Gastroenterology
Truro, Cornwall TR1 3LJ United Kingdom

RALF DÜRRWALD
IDT Biologika GmbH, Am Pharmapark
Dessau-Roßlau, 06861 Germany

JANET A. ENGLUND
Seattle Children’s Hospital, University of Washington, and Fred Hutch Cancer Center
Seattle, WA 98105

DEAN D. ERDMAN
Centers for Disease Control and Prevention
Atlanta, GA 30333

MARY K. ESTES
Baylor College of Medicine
Houston, TX 77030

JOYCE FINGEROTH
University of Massachusetts Medical School
Worcester, MA 01605

MANUEL ANTONIO FRANCO
Facultad de Medicina, Instituto de Genética Humana
Pontificia Universidad Javeriana
Bogotá, Colombia

ILYA V. FROLOV
University of Alabama at Birmingham
Birmingham, AL 35294

JAMES E. GERN
University of Wisconsin-Madison
School of Medicine and Public Health
Madison, WI 53792

ANNE A. GERSHON
Columbia University College of Physicians and Surgeons
New York, NY 10032

MICHAEL D. GERSHON
Columbia University College of Physicians and Surgeons
New York, NY 10032

MICHAEL D. GESCHWIND
University of California, San Francisco
San Francisco, CA 94158

JOHN W. GNANN, JR.
Department of Medicine, Division of Infectious Diseases
Medical University of South Carolina,
Charleston, SC 29425

CLAIRE L. GORDON
Columbia University Medical Center
New York, NY 10032

BARNEY S. GRAHAM
National Institutes of Health
Bethesda, MD 20892

HARRY B. GREENBERG
Stanford University
Departments of Medicine, Microbiology and Immunology
Palo Alto, CA 94305

JOHN E. GREENLEE
Veterans Affairs Medical Center
University of Utah Health Sciences Center
Salt Lake City, UT 84148

Diane E. Griffin
Johns Hopkins Bloomberg School of Public Health
Baltimore, MD 21205

Paul David Griffiths
Institute for Immunity and Transplantation
University College London Medical School
London NW3 2PF, United Kingdom

JOHN GUATELLI
University of California San Diego
La Jolla, CA 92093

Scott M. Hammer
Columbia University Medical Center
New York, NY 10032

Frederick G. Hayden
University of Virginia School of Medicine
Charlottesville, VA 22908

HANS H. HIRSCH
University of Basel
Basel CH-4009 Switzerland

STUART N. ISAACS
Perelman School of Medicine at the University of Pennsylvania
Department of Medicine (Infectious Diseases)
Philadelphia, PA 19104

Jacques Izopet
CHU Purpan
Department of Virology
Toulouse, Midi Pyrennees 31059 Toulouse, France

Alan C. Jackson
University of Manitoba
Winnipeg, Manitoba R3A 1R9, Canada

Colleen B. Jonsson
University of Tennessee-Knoxville
Knoxville, TN 37996

Nassim Kamar
CHU Rangueil
Department of Nephrology and Organ Transplantation
Toulouse, Midi Pyrenees 31400 Toulouse, France

Mee-Ohk Kim
University of California, San Francisco
San Francisco, CA 94158

David W. Kimberlin
University of Alabama at Birmingham
Birmingham, AL 35233
KARIN KLINGEL
University Hospital Tübingen
Tübingen D-72076, Germany

CHRISTOPHER KOH
NIDDK-NIH
Bethesda, MD 20892

CHRISTINE J. KUBIN
Columbia University Medical Center
New York, NY 10032

JENS H. KUHN
National Institutes of Health
Frederick, MD 21702

DANIEL KURITZKES
Brigham and Women’s Hospital, Harvard Medical School
Boston, MA 02115

DONALD R. LATNER
Centers for Disease Control and Prevention
National Center for Immunization and Respiratory Diseases
Atlanta, GA 30333

JULIE E. LEDGERWOOD
National Institutes of Health
Bethesda, MD 20892

WAI-MING LEE
Biological Mimetics, Inc.
Frederick, MD 21702

STANLEY M. LEMON
University of North Carolina at Chapel Hill
Chapel Hill, NC 27599

EYAL LESHEM
Centers for Disease Control and Prevention
Atlanta, GA 30333

QISHENG LI
NIDDK-NIH
Bethesda, MD 20892

JAKE LIANG
NIDDK-NIH
Bethesda, MD 20892

ANDREW R. LLOYD
University of New South Wales
Sydney, NSW 2052, Australia

STEPHEN A. LOCARNINI
Victorian Infectious Diseases Reference Laboratory
Melbourne, Victoria 3000, Australia

TOMÁS D. LÓPEZ
Instituto de Biotecnología/UNAM
Cuernavaca 62210, Mexico

HONGLIN LUO
University of British Columbia
Vancouver, BC V6Z 1Y6 Canada

JOHN S. MACKENZIE
Faculty of Health Sciences
Curtin University, GPO Box U1987,
Perth, WA6845, Australia

RENAUD MAHIEUX
Retroviral Oncogenesis team, Equipe labellisée “Ligue Nationale contre le Cancer”, INSERM U1111 - CNRS
UMR5308, Ecole Normale Supérieure de Lyon, Université Lyon
1 LabEx ECOFECT
Lyon Cedex 07, France

TONY MAZZULLI
Mount Sinai Hospital, University of Toronto
Toronto, ON M5G 1X5, Canada

BRUCE M. MCMANUS
University of British Columbia
Providence Health Care
PROOF Centre of Excellence
Vancouver, BC V6Z 1Y6, Canada

MONICA D. MEHTA
NewYork-Presbyterian Hospital,
Columbia University Medical Center
New York, NY 10032

GREGORY J. MERTZ
University of New Mexico Health Sciences Center
Albuquerque, NM 87131

JORDAN P. METCALF
University of Oklahoma Health Sciences Center
Oklahoma City, OK 73104

BENJAMIN A. MIKO
Columbia University Medical Center
New York, NY 10032

PATRICK S. MOORE
University of Pittsburgh Cancer Institute
Pittsburgh, PA 15217

YASUKO MORI
Kobe University Graduate School of Medicine
Kobe, Hyogo, 650-0017 Japan

WILLIAM J. MOSS
Johns Hopkins Bloomberg School of Public Health
Baltimore, MD 21205

EDWARD L. MURPHY
University of California San Francisco
San Francisco, CA 94143

ZEENA Y. NAWAS
Center for Clinical Studies
Houston, TX 77004

BRIAN NELSON
Columbia University Medical Center,
New York-Presbyterian Hospital
New York, NY 10032

HOWARD M. NEWMAN
National Health Laboratory Service and
Stellenbosch University
Port Elizabeth, Eastern Cape 6000, South Africa
CONTRIBUTORS

NORBERT NOWOTNY
University of Veterinary Medicine
Vienna A 1210, Austria, and
Mohammed Bin Rashid University of Medicine and Health
Sciences, Dubai, United Arab Emirates

PETER PALESE
Icahn School of Medicine at Mount Sinai
New York, NY 10029

UMESH D. PARASHAR
Centers for Disease Control and Prevention
Atlanta, GA 30333

J.S.M. PEIRIS
The University of Hong Kong
Pok Fu Lam, Hong Kong

MARCUS R. PEREIRA
Columbia University Medical Center
New York, NY 10032

LYLE R. PETERSEN
Centers for Disease Control and Prevention
Fort Collins, CO 80521

MARTIN PETRIC
University of British Columbia
Vancouver, BC V6T 2B5, Canada

PEDRO A. PIEDRA
Baylor College of Medicine
Houston, TX 77030

MATTHEW REEVES
Institute for Immunity and Transplantation
University College London Medical School
London NW3 2PF, United Kingdom

DOUGLAS D. RICHMAN
VA San Diego Healthcare System and
University of California San Diego
La Jolla, CA 92039-0679

MARIO RIZZETTO
University of Torino
Torino 10126, Italy

BERNARD ROIZMAN
The University of Chicago
Chicago, IL 60637

JOSÉ R. ROMERO
University of Arkansas for Medical Sciences and Arkansas
Children’s Hospital
Little Rock, AR 72202

CATHY ROTH
World Health Organization
Geneva, Switzerland

OLLI RUUSKANEN
Turku University Hospital
20520 Turku, Finland

CHELSEA SAMMONS
Columbia University Medical Center,
New York-Presbyterian Hospital
New York, NY 10032

MATTHEW L. SCHERER
Columbia Presbyterian Medical Center
New York, NY 10032

MICHAEL A. SEIDMAN
Providence Health Care
Vancouver, BC V6Z 1Y6 Canada

COLIN P. SHARP
University of Edinburgh
Edinburgh EH8 9YL, United Kingdom

GAO SHOU-JIANG
University of Southern California
Los Angeles, CA 90089

CHRISTINA J. SIGURDSON
University of California, San Diego
La Jolla, CA 92093

ROBERT SILICIANO
Johns Hopkins University School of Medicine
Baltimore, MD 21205

PETER SIMMONDS
University of Edinburgh
Edinburgh EH8 9YL, United Kingdom

ANTONINA SMEDILE
University of Torino
Torino 10126, Italy

DAVID W. SMITH
School of Pathology and Laboratory Medicine,
University of Western Australia
Crawley, Western Australia, 6009 Australia

MARCIA SÖDERLUND-VENERMO
University of Helsinki, Department of Virology
00014 Helsinki, Finland

HENDRIK STREECK
University Hospital, University Duisburg-Essen
Essen 45147, Germany

TODD J. SUSCOVICH
Ragon Institute of MGH, MIT, and Harvard
Cambridge, MA 02139

BARBARA S. TAYLOR
University of Texas Health Science Center San Antonio
Infectious Diseases
San Antonio, TX 78229

ALEXANDER J.V. THOMPSON
St Vincent’s Hospital and
The University of Melbourne
Fitzroy VIC 3065, Australia

JOHN J. TREATOR
University of Rochester School of Medicine and Dentistry
Rochester, NY 14642
STEPHEN K. TYRING
Center for Clinical Studies
University of Texas Health Science
Houston, TX 77030

ZINA S. VALAYDON
St Vincent's Hospital Melbourne
Fitzroy VIC 3065, Australia

ELIZABETH Verna
Columbia University Medical Center,
NewYork-Presbyterian Hospital
New York, NY 10032

LIN-FA WANG
Programme in Emerging Infectious Diseases
Duke-NUS Medical School,
8 College Road, Singapore 169857

MATTI WARIS
University of Turku
20520 Turku, Finland

SCOTT C. WEAVER
University of Texas Medical Branch
Galveston, TX 77555

RICHARD J. WHITLEY
Departments of Pediatrics, Microbiology, and Medicine,
University of Alabama at Birmingham
Birmingham, AL 35294

JOHN V. WILLIAMS
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, PA 15224

SARA E. WILLIFORD
University of North Carolina at Chapel Hill
Chapel Hill, NC 27599

DARREN J. WONG
St Vincent's Hospital Melbourne
Fitzroy VIC 3065, Australia

JOSEPH K. WONG
University of California San Francisco
San Francisco VAMC Medicine
San Francisco, CA 94121

KOICHI YAMANISHI
Osaka University
Osaka 565-0871, Japan

STEVEN YUKL
University of California San Francisco
San Francisco VAMC Medicine
San Francisco, CA 94121

JOHN A. ZAIA
Hematologic Malignancies and
Stem Cell Transplantation Institute
City of Hope
Duarte, CA 91010
Conflicts of Interest

Robert Atmar (chapter 49) has received research grant funding from and is a consultant to Takeda Vaccines, Inc.

Yuan Chang (chapter 26) holds patents that are assigned to his university on KSHV-related inventions.

Harry R. Dalton (chapter 50) has received travel and accommodation costs and consultancy fees from GlaxoSmithKline, Wantai, and Roche; travel, accommodation, and lecture fees from Merck, Gilead, and GFE Blut GmbH; and travel and accommodation fees from the Gates Foundation.

Mary K. Estes (chapter 49) is named as an inventor on patents related to cloning of the Norwalk virus genome and has served as a consultant to Takeda Vaccines, Inc.

Gao Shou-Jiang (chapter 26) holds patents that are assigned to his university on KSHV-related inventions.

Anne Gershon (chapter 22) has received service contracts (molecular VZV diagnosis for vaccine safety) and is a Merck ad hoc consultant and chair of the Data and Safety Monitoring Board (DSMB): GSK (on VZV) AAG

John Greenlee (chapter 28) receives honoraria as author and associate editor for Medlink and as chapter author for the Merck Manual. Dr. Greenlee’s research is supported by the United States Department of Veterans Affairs.

Frederick G. Hayden (chapter 43) is a nonpaid consultant to multiple companies engaged in developing and/or marketing influenza antivirals and therapeutics. He receives personal compensation for service as SAB member on the University of Alabama NIAID-sponsored Antiviral Drug Discovery and Development Consortium, which is looking for novel influenza inhibitors. The University of Virginia has received honoraria payments since 2013 for Dr. Hayden’s activities from Hologic (consulting), Singapore Institute of Infectious Diseases and Epidemiology (consulting), Gilead Sciences (DSMB), Sanofi-Pasteur (DSMB), and GSK (consulting).

Hans H. Hirsch (chapter 28) receives honoraria for scientific advisory boards from Chimerix Inc., Merck, and Oxford Immunotec; his research has been supported by unrestricted appointment grants of the University of Basel and by grants research from Chimerix Inc. and Novartis.

Nassim Kamar (chapter 50) has received travel and accommodation costs and consultancy fees from Novartis and Merck; travel, accommodation, and lecture fees from Gilead, Novartis, Astellas, BMS, Amgen, and Fresenius; and travel and accommodation fees from the Gates Foundation.

Steven A. Locarinini (chapter 32) receives consulting fees (e.g., advisory boards) — Gilead Sciences Inc. and Arrowhead Research Corp. and fees for non-CME services received directly from a commercial interest or their agent from Arrowhead Research Corp.

Patrick Moore (chapter 26) holds patents that are assigned to his university on KSHV-related inventions.

Pedro A. Piedra (chapter 37) previously served on the speaker bureau at MedImmune and as a scientific advisor for AstraZeneca.

Alexander Thompson (chapter 32) receives consulting fees (e.g., advisory boards) from Gilead Sciences Inc. and Arrowhead Research Corp. and fees for non-CME services received directly from a commercial interest or their agent from Arrowhead Research Corp.

John Williams (chapter 37) serves on the Scientific Advisory Board of Quidel and an Independent Data Monitoring Committee for GlaxoSmithKline.
Virology is currently one of the most dynamic areas of clinical medicine. Challenges related to novel viruses, changing epidemiologic patterns, new syndromes, unmet vaccine needs, antiviral drug resistance, and threats of bioterrorism are balanced against improved insights into viral pathogenesis, better diagnostic tools, novel immunization strategies, and an expanding array of antiviral agents. The demands on clinicians, public health workers, and laboratorians will continue to increase as will the opportunities for effective intervention. This text, now in its fourth edition, is designed to inform scientists and health care professionals about the medically relevant aspects of this rapidly evolving field.

Clinical Virology has two major sections. The first addresses infections and syndromes related to particular organ systems, as well as the fundamentals of modern medical virology, including immune responses and vaccinology, diagnostics, and antivirals. The second provides agent-specific chapters that detail the virology, epidemiology, pathogenesis, clinical manifestations, laboratory diagnosis, and prevention and treatment of important viral pathogens. In a multiauthored text like Clinical Virology, the selection of authors is key. The senior authors for individual chapters were chosen because of their internationally recognized expertise and active involvement in their respective fields. In addition, common templates for the syndrome-specific and separately for the agent-specific chapters allow the reader to readily access material. Since publication of the third edition in 2009, all of the chapters have been extensively revised to incorporate new information and relevant citations. The timeliness and presentation of the fourth edition have been enhanced by publication of chapters online as they have become available and by the increased numbers and incorporation of color figures into the text. New chapters on Bornaviruses and Anelloviruses have been added, and the rapidly expanding field of antiviral drugs demanded dividing the subject into four chapters.

We have been particularly fortunate in receiving invaluable help from our administrative assistants, Mayra Rodriguez, Dunia Ritchey, and Lisa Cook. In addition, we express our appreciation for the enthusiastic professional support provided by Christine Charlip, Lauren Luethy, and Larry Klein of ASM Press.

DOUGLAS D. RICHMAN
RICHARD J. WHITLEY
FREDERICK G. HAYDEN
Important Notice (Please Read)

This book is intended for qualified medical professionals who are aware that medical knowledge is constantly changing. As new information becomes available, changes in treatment, diagnostic procedures, equipment, and the use of drugs and biologicals become necessary. The editors, authors, and publisher have, as far as it possible, taken care to ensure that the information is up-to-date but cannot guarantee that it is.

Consequently, readers are strongly advised to confirm that the information, especially with regard to drug usage, complies with the latest legislation and standards of practice. The authors, editors, and publisher make no warranty, expressed or implied, that the information in this book is accurate or appropriate or represents the standard of care for any particular facility or environment or any individual’s personal situation.
### Subject Index

**A**

- AAV. See Adenovirus-associated virus
  - Abacavir
    - adverse effects, 176, 181
    - clinical applications, 170, 182
    - cutaneous adverse effects, 134
    - dosing regimen, 170
    - drug interactions, 176, 181
    - fixed-dose combination, 197
    - for HIV infections, 170, 176, 178, 181–182
    - mechanism of action, 181
    - pharmacokinetics, 176
    - pharmacology, 181
    - resistance, 181–182
    - structure, 178
  - ABT-493. See Glecaprevir
  - ABT-530. See Pibrentasvir
  - Acetowhite lesion, 648
  - ACH-2684, 1333
  - ACH-3102, 1333
  - ACH-3422, 247, 1333
  - Achimota virus (AchPV), 949, 956
  - Acquired immunodeficiency syndrome (AIDS), 795
  - HIV progression to, 805–810, 812. See also Human immunodeficiency virus
  - Active immunization, 351
  - Acute disseminated encephalomyelitis (ADEM), 38–40, 42
  - Acute flaccid paralysis (AFP)
    - coxsackievirus, 1125
    - poliovirus, 1119, 1125
  - Acute liver failure (ALF), 62, 66–67
  - Acute postinfectious measles
    - encephalomyelitis, 916–917
  - Acute retinal necrosis (ARN), 154, 159
  - Acyclovir
    - adverse effects, 215–216, 219
    - for B virus infections, 454
    - for chronic fatigue syndrome, 378
    - clinical applications, 217, 220
    - for CMV infections, 78, 220, 499–502
    - dosing regimen, 217, 474
    - drug interactions, 216–219
    - for EBV, 84–85, 159, 215, 220, 539
    - for encephalitis, 42
    - for hepatitis, 67
    - for herpesvirus infections, 215–220
    - for HHV-6 infections, 86, 215, 517
    - mechanism of action, 215
    - for meningitis, 38
    - for Nipah virus infections, 960
    - pharmacokinetics, 216, 219
    - for pharyngitis, 12
    - for pneumonia, 23
    - spectrum of activity, 215
    - structure, 216
    - for vaccinia virus, 162
  - Adenine arabinoside, for poxvirus infections, 407
  - Adenovirus
    - age-specific attack rates, 581
    - antigen detection, 588–589
    - bacterial coinfections, 588
    - biology, 576–580
    - bronchiolitis, 10, 16
    - cell culture, 292–294, 588
    - classification and taxonomy, 2, 575–576
    - clinical manifestations, 300, 584–588
    - CNS infections, 32
    - colitis, 583
    - common cold, 10
    - conjunctivitis, 160
    - croup, 10, 13
    - cytokine responses, 583
    - cytopathology, 300
    - diagnosis, 306
    - electron microscopy, 50
    - encephalitis, 583, 587
    - environmental decontamination, 580
    - epidemiology, 580–582
    - experimental models, 580
    - fever syndromes, 586
    - gastroenteritis, 47–54, 575, 580–582, 585–586
    - genome, 576–577
    - hemorrhagic cystitis, 586, 590
    - hepatitis, 583, 587
    - high-risk groups, 581
    - histology, 582–583
    - historical aspects, 575
    - HIV-adenovirus coinfection, 583, 587
    - immune response, 331, 336, 583–584
    - immunoassay, 297–298
    - immunocompromised individual, 587–588, 590
    - immunoprophylaxis, 589–590
    - inactivation, 580
    - incidence and prevalence of infection, 580–581
    - incubation period, 582
    - infection cycle, 576
    - early events, 577–578
    - entry into cells, 576–578
    - late events, 577, 579

---

**B**

- B cells. See B cells
- Antibodies
  - Antibody-dependent enhancement
- Adenovirus
  - antigens, 297–298
  - for antibodies, 336–340
  - for B cells
  - immunologic basis of vaccination, 354–355
  - antibodies, 356–357
  - T cells, 357–358
  - T cells. See T cells
- ADE. See Antibody-dependent enhancement
- Adenovirus
  - adverse effects, 240–241
  - clinical applications, 241–242
  - dosing regimen, 240
  - for HBV, 240–242, 736, 739–740
  - for HDV, 1417
  - mechanism of action, 241
  - pharmacology, 241
  - resistance, 241–242, 739, 742
  - spectrum of activity, 240–241
  - structure, 241
  - for vaccinia virus, 162
  - ADEM. See Acute disseminated encephalomyelitis

---

**C**

- Acute disseminated encephalomyelitis (ADEM), 38–40, 42
- Acute flaccid paralysis (AFP)
  - coxsackievirus, 1125
  - poliovirus, 1119, 1125
- Acute liver failure (ALF), 62, 66–67
- Acute postinfectious measles
  - encephalomyelitis, 916–917
- Acute retinal necrosis (ARN), 154, 159
- Acyclovir
  - adverse effects, 215–216, 219
  - for B virus infections, 454
  - for chronic fatigue syndrome, 378
  - clinical applications, 217, 220
  - for CMV infections, 78, 220, 499–502
  - dosing regimen, 217, 474
  - drug interactions, 216–219
  - for EBV, 84–85, 159, 215, 220, 539
  - for encephalitis, 42
  - for hepatitis, 67
  - for herpesvirus infections, 215–220
  - for HHV-6 infections, 86, 215, 517
  - mechanism of action, 215
  - for meningitis, 38
  - for Nipah virus infections, 960
  - pharmacokinetics, 216, 219
  - for pharyngitis, 12
  - for pneumonia, 23
  - spectrum of activity, 215
  - structure, 216
  - for vaccinia virus, 162
  - ADEM. See Acute disseminated encephalomyelitis

---

**D**

- Adverse effects, 176, 181
- Clinical applications, 170, 182
- Cutaneous adverse effects, 134
- Dosing regimen, 170
- Drug interactions, 176, 181
- Fixed-dose combination, 197
- For HIV infections, 170, 176, 178, 181–182
- Mechanism of action, 181
- Pharmacokinetics, 176
- Pharmacology, 181
- Resistance, 181–182
Anti-HBe antibody, 67–68
Anti-HBe antibody, 67–68, 733–734
Anti-HBs antibody, 67–68, 733–734
Anti-HCV antibody, 67–68
Anti-HDV antibody, 67–68
Antiperspiratory virus agents
acyclovir, 215–220
brivudine, 216–219, 222–223
cidofovir, 216–219, 228–229
docosanol, 229
famciclovir and penciclovir, 216–219, 221–222
toscarnet, 216–219, 226–228
ganciclovir, 216–219, 223–225
imiquimod, 229
investigational, 229–230
resistance, 436–437
toxicity, 436–437
trifluridine, 216–219, 223
valacyclovir, 216–221
valganciclovir, 216–219, 225–226
Anti-HEV antibody, 67–68
Antithiomimetics, for common cold, 1157
Antimetabolites, for HIV infections, 657–658
Antimimetics, for HPV infections, 657–658
Antirespiratory virus agents
for influenza virus, 271–282
investigational, 283–285
for RSV, 273–276, 282, 285
Antiretroviral agents, 795. See also specific agents
cutaneous adverse effects, 134
for Aspergillosis, 42
for hepatitis therapy and, 71
for HIV
broadly neutralizing monoclonal antibodies, 175, 819
compartments and reservoirs, 822
entry inhibitors, 169–175
fixed-dose combinations, 169, 197
historical aspects, 169
immunologic restoration, 822–823
integrate strand transfer inhibitors, 170–173, 189–192
investigational agents, 172–173, 175, 189, 192, 200
KSHV coinfection, 565
maturation inhibitors, 173, 201
nonnucleoside reverse transcriptase inhibitors, 170–172, 184–189
nucleoside/nucleotide reverse transcriptase inhibitors, 170–172, 175–184
perinatal administration, 820
pharmacokinancers, 170, 200–201
postexposure prophylaxis, 819
preexposure prophylaxis, 818–819
principles underlying therapy, 822
protease inhibitors, 170–171, 192–200
resistance emergence, 823
resistance impacts on treatment, 823–824
resistance testing, 295–297, 817–818, 824
targets, 169, 171
for HIV-associated neurologic dysfunction dementia, 811
for HTLV, 786–787
immune-recovery uveitis, 155
new developments, 1
viral load, 808–809
Antisense oligonucleotides, for filovirus infections, 1001
Antiviral agents. See also specific agents
for adenovirus, 590
for arenavirus, 1104–1105
for B virus, 454
for CMV prophylaxis in transplant recipient, 78–82
for coronavirus, 1257
for EBV, 84–85, 539–540
for filovirus infection, 997, 1000–1001
for HBV, 239–243, 738–748
for HCV, 1329
direct-acting, 63, 71, 245, 249–262, 1331–1334
for HDV, 1417
for hemorrhagic fever, 147–148
for herpesvirus infections. See Antiperspiratory virus agents
for HHV-6 or HHV-7, 86
for HHV-8, 87
for influenza virus infections, 1040–1042
for KSHV, 564–565
for metapneumovirus, 889–890
monitoring, 306
for mycobacterium, 107–108
for parainfluenza virus, 889–890
for PMI, 615
for pneumonia, 22–24
for poxvirus infections, 407–408
for rabies, 974
for respiratory disease. See Antirespiratory virus agents
for RSV, 889–890
for VZV, 474–475
Antiviral susceptibility testing, 294
genotypic assays, 296–297
phenotypic assays, 295–296
Antiviron program assay, 296
APCs. See Antigen-presenting cells
Aplastic crisis. See Transient aplastic crisis
Apovirus, 1269
Apex virus, 1060
Aquatic bird bornavirus, 1396
Arbovirus. See also Flavivirus; Reovirus
CNS infections, 32–34, 37–38, 41–42
ocular manifestations, 162
seroepidemiology, 307
Arenavirus
animal models, 1093
animal reservoirs, 1092–1093, 1096–1097
cell culture, 1093
classification and taxonomy, 3, 1089–1090, 1094
clinical manifestations, 1090–1091
CNS infections, 1098–1099
canevalescence and sequelae, 1101
differential diagnosis, 1101
epidemiology, 1089–1098
genographic distribution, 1089–1093
hemorrhagic fever, 141–149, 1099–1101
host range, 1092–1093, 1096–1097
immune response, 1098–1099
immunohistochemistry, 1102
inactivation by physical and chemical agents, 1093
incubation period, 1098
isolation, 1101
laboratory diagnosis, 1101–1102
New World, 1089–1090, 1092–1093
nucleic acid detection, 1101–1102
Old World, 1089–1091
pathogenesis, 1098–1099
pathology, 1098
PCR methods, 1101–1102
in pregnancy, 1100
prevention
active immunization, 1102–1103
disinfection, 1102
outbreak management, 1103
patient isolation and infection, 1102
postexposure prophylaxis, 1103
rodent control, 1103–1104
prognosis, 1100–1101
receptors, 1092
replication, 1091, 1095, 1098–1099
seroepidemiology, 307, 1102
transmission, 1094–1095, 1098
treatment
antiviral therapy, 1104–1105
convalescence management, 1105
convalescent plasma, 1104–1105
discharge criteria, 1105
experimental, 1105
host-directed therapies, 1105
supportive, 1104
virion composition, 1091, 1095
virology, 1089–1097
Arenaviruses, 1102–1103
Argentine hemorrhagic fever, 142, 144, 148, 1093, 1100, 1102–1104
Argentine hemorrhagic fever vaccine, 148
ARN. See Acute renal necrosis
Aroa virus, 1268
Arsenic trioxide, for adult T-cell lymphoma, 786
Artesunate, for CMV prophylaxis, 81
Arthralgia
chikungunya virus, 1368
flavivirus, 1281
HCV, 1327
parovirus B19, 687, 690
rubella virus, 1386–1387
Arthritis
alphavirus, 1347
chikungunya virus, 1368–1369
HIV, 813
HTLV, 782, 783
influenza virus, 1030
parovirus B19, 684, 687, 690
rubella virus, 1386–1387, 1389–1390
Arthritis-dermatitis syndrome, 748
HIV, 731
Arthropod-borne virus. See Arbovirus
Aseptic meningitis, 31–32, 37
enterovirus, 1123–1124
Asialoglycoprotein receptors, 330
ASPF013, 82
Aspartate aminotransferase (AST), in hepatitis, 67
Aspirin, in hemorrhagic fever patients, 147
AST. See Aspartate aminotransferase
Asthma
coronavirus and, 1254
metapneumovirus and, 883, 884–885
rhinovirus and, 1154–1155
RV and, 884–885
Astrovirus (AstV)
animals, 1231
antigen detection, 1238
biology, 1233–1234
classification and taxonomy, 4, 1231
clinical manifestations, 1237–1238
distribution and geography, 1234–1235
electron microscopy, 50, 1238
genetics, 1231, 1236–1238
epidemiology, 1234–1235
gastroenteritis, 47–54, 1231, 1235–1239
Astrovirus (AstV) (continued)
genome, 1232–1234
host range, 1235
immune response, 1236–1237
immunocompromised individual, 1235,
1238–1239
inactivation by physical and chemicals
agents, 1234
incidence and prevalence of infection,
1234–1235
intussusception, 1237
isolation, 1238
laboratory diagnosis, 1238
nucleic acid detection, 1238
pathogenesis, 1235–1237
PCR methods, 1238
prevention, 1238
proteins, 1232–1234
replication, 1234
seasonality, 1235
serotypes, 1231, 1235
strain, 1234
transmission, 1235
treatment, 1238–1239
virology, 1231–1234
Asunaprevir, 1333
adverse reactions, 256
clinical applications, 256
pharmacology, 256
resistance, 256
spectrum of activity, 256
structure, 251
Atazanavir
adverse effects, 194, 198
clinical applications, 170, 199
cutaneous adverse effects, 134
dosing regimen, 170
drug interactions, 194, 198
for HIV, 170, 194, 196–198
pharmacokinetics, 194
pharmacology, 198
resistance, 198–199
structure, 196
ATL. See Adult T-cell lymphoma
Atiprila, 197
Attenuavir, 353
Aurora virus, 1348
Australian antigen, 61
Australian bat lyssavirus, 997, 976
Autism, MMR vaccine and, 921
Autoimmune disease, EBV , 538
Autoimmune regulator, See Acute
disseminated encephalomyelitis
Autoimmune regulator (AIRE), 333
Autophagy, 336
AVI-7100, 283
Avian influenza virus, 1014–1015,
1017–1018, 1020–1021
H5N1, 1021
H7N9, 1021–1022
Avian metapneumovirus, 874
Avidity tests, 308
Atazanavir, for myocarditis, 107
AZT. See Zidovudine

B
B19V. See Parvovirus B19
Bacterial coinfections
with influenza virus, 1024–1026
with rhinovirus, 1155
in viral pneumonia, 18, 22
BAFF. See B cell activating and survival
factor
Bagaza virus, 1269
Balaton virus, 848
Banna virus (BAV), 3, 842–844, 848
Banzi virus, 1269, 1281
Barnah Forest virus (BFV), 1347, 1349,
1355, 1374
Barnyard poxvirus infections, 397
Barrier immunity, 344
commensal organisms, 324
mucosal, 323–324
skin, 321, 323
Basal cell carcinoma, HPV , 640
Bas-Congo virus, 141
Basophils, 326
Bats
coronavirus, 1244
filovirus, 896, 899
Hendra virus, 949–950, 954, 960
Menangle virus, 949–950, 955, 960
Nipah virus, 949–950, 954, 960
rabies virus, 38, 967, 969–970
Sosuga virus, 949–950, 955–956
BAV. See Banna virus
Bayou virus, 1065
B cell activating and survival factor (BAFF),
328
B-cell receptor (BCR), 340–341
B cells, 325
affinity maturation, 342–344
EBV, 525–531
lymphoproliferative disorders, 534–535
malignancies, 82–83, 124, 523, 535–538
immunologic basis of vaccination,
356–357
KSHV, 549, 553–554, 558–560
memory, 340–341
BCR. See B-cell receptor
BCX4430
for filovirus infection, 1000
for yellow fever, 1302
BD FocalPoint Slide Profiler, 650
BD ProbeTec, 303
Bebaru virus, 1349
Beclabuvir, 1333
adverse effects, 253
clinical applications, 253
pharmacokinetics, 253
resistance, 253
spectrum of activity, 253
structure, 250
Besifovir, for HBV, 742
Bethesda system, 650
Bevirimat, 201
BFV. See Barnah Forest virus
Bichloracetic acid
for genital warts, 657–658
for HPV infections, 119
Bictegravir, 172, 192
Biliary atresia, rotavirus and, 864
Bilirubin, in hepatitis, 67
BILS 179 BS, for herpesvirus infections,
229
Bioterrorism
arenavirus, 1089
smallpox virus, 406
Birds
alpahavirus, 1353
astrovirus, 1231
bornavirus, 1395–1397
eastern equine encephalitis virus, 1357
influenza virus, 1014–1015, 1017–1018,
1020–1021
Murray Valley encephalitis virus, 1279
Sindbis virus, 1370–1371
St. Louis encephalitis virus, 1280, 1282
Venezuelan equine encephalitis virus,
1363–1364
western equine encephalitis virus,
1360–1361
West Nile virus, 1287–1288
BIT225, 247
BK virus (BKV)
animal models, 607–608
attachment and entry into cells,
602–603
biology, 602–606
carcinogenesis, 612–613
cell culture, 603, 605
cell transformation, 605
classification and taxonomy, 599–600
clinical manifestations, 300, 613–615
cytopathology, 299–300
diagnosis, 306
electron microscopy, 300
encephalitis, 614
epidemiology, 606–607
historical aspects, 599
host range, 603
immune response, 609
immunocompromised individual,
600 interaction with glial cell cultures,
603, 605
laboratory diagnosis, 615
nephropathy, 87–88, 607, 610–612,
614–616
ocular manifestations, 162
pathogenesis, 600, 607–613
persistence, 608
pneumonia, 614
in pregnancy, 609
prevention, 615
primary infection, 606
proteins, 601–602
reactivation of persistent infection,
608–609
repression, 603, 608
retinitis, 614
risk factors, 607
seroconversion, 615
sites of infection, 600
transmission, 606–607
transplant recipient, 75, 87–88, 607,
610–612, 614–616
treatment, 616
urinary excretion, 609
urinary tract disease, 87–88, 607,
610–612, 614–616
virology and composition, 599–601
Black Creek Canal virus, 1065
Bleomycin, for HPV infections, 657–658
Blistering agents, for HPV infections, 658
Blood
CMV detection, 495–496
testing for viral antibodies, 308–309
Bloodborne transmission
CMV, 489, 498
HBV, 722, 734
HCV, 1322–1323
hepatitis virus, 62, 64–65, 69
HIV, 804, 818
HTLV, 777–778, 785
KSHV, 557–558
parvovirus 19, 683
Bloodland Lake virus, 1065
Bovine parainfluenza virus, 874

Bovine/ovine RSV, 874

Bouboui virus, 1269

Bornavirus vaccine, 1403

bnAbs.

BMS-955176, 173, 201

Bluetongue virus, 842

Borna disease virus (BoDV)

zoonotic epidemic patterns, 1398

virion composition, 1396, 1398

transmission, 1399

subclinical infection rate, 1398

serotypes, 1395

serodiagnosis, 1403

seasonality, 1399

reinfections, 1399

proteins, 1398

prevention, 1403

PCR methods, 1402

passive immunoprophylaxis, 1403

laboratory diagnosis, 1402

inactivation by physical and chemical

immune responses, 1400

incubation period, 1399

infection, 1400

laboratory diagnosis, 1402–1403

passive immunoprophylaxis, 1403

pathogenesis, 1399–1400

prevention, 1403

psychiatric disease, 1401

replication patterns, 1399

host range, 1399

symptoms, 1400

taxonomy, 3

Bomavirus

antigen detection, 1402

antigenic drift, 1395

biology, 1396–1397

cell culture, 1397

classification and taxonomy, 3, 1395–1397

clinical diagnosis, 1400–1401

clinical manifestations, 1400–1402

disease production, 1400

distribution and geography, 1395

ecological background, 1395

host range, 1397–1398

immune responses, 1400

inactivation by physical and chemical agents, 1397

incidence and prevalence, 1398

incubation period, 1399

isolation, 1402

laboratory diagnosis, 1402–1403

members of, 1395–1396

nucleic acid detection, 1402

pathogenesis, 1399–1400

PCR methods, 1402

prevention, 1403

proteins, 1398

psychiatric disease, 1401

reinfections, 1399

replication, 1396–1397

patterns of, 1399–1400

risk factors, 1399

seasonality, 1399

serodiagnosis, 1403

serotypes, 1395

subclinical infection rate, 1398

symptoms, 1400

transmission, 1399

treatment, 1403

virion composition, 1396, 1398

virology, 1395–1397

– zoonotic epidemic patterns, 1398–1399

Bomavirus vaccine, 1403

Bouvoui virus, 1269

Bovine/ovine RSV, 874

Bovine papillomavirus (BPV), 625, 635, 642

Bovine parainfluenza virus, 874

Bovine peracute potatoxins virus (BPSV), 388

Budesonide

Buparazol, for common cold, 11

Broadly neutralizing monoclonal antibodies

for HIV, 175

Bromodiphenyl ether, 147

Bronchodilator therapy, for RSV, 888

Bronchitis

chronic, exacerbation by rhinovirus

infection, 1154–1155

influenza virus, 1027–1029

Bronchodilators, for bronchitis, 17

Bronchodilator therapy, for RSV, 888

BTA-585, 284

Budesonide

for croup, 15

for parainfluenza virus infections, 889

BuFavirus (BuV), 679–683, 686, 688–689

Buffalopox virus, 388

clinical diagnosis, 405

epidemiology, 396–397

host range, 394

Bush Creek virus, 1348

Bukalas bat virus, 1269

Bunyamwera virus, 3, 1060, 1063

Bunyaviridae

California encephalitis group, 1059–1060

occurrence, 1063

cell culture, 1061–1063

classification and taxonomy, 3, 1059–1060

distribution and geography, 1060

encephalitis, 1064

epidemiology, 1062–1063

genome, 1059–1060

hantavirus. See Hantavirus

host range, 1061–1063

nairoviruses. See Nairovirus

phleboviruses. See Phlebovirus

proteins, 1059–1060

replication, 1060–1061

erosion, 1057

subgroups, 1060

transmission, 1063

virion structure, 1059–1060

virology, 1059–1062

Burkitt’s lymphoma, 82, 124, 523, 537

Buschke-Loewenstein tumor, 115, 118, 648

Bussquara virus, 1268, 1281

C

C134, 434–435

Cabassou virus, 1348, 1355

Cabotegravir, 173, 192

Cacicaparvovirus, 1268

CAEBV. See Chronic active EBV

Calabaza virus, 1065

Calicivirus

animal models, 1196

antigen detection, 1202

antigenicity, 1190, 1193

biology, 1196

cell culture, 1196

classification and taxonomy, 4, 1189–1193

clinical manifestations, 1199–1201

distribution and geography, 1197

electron microscopy, 50

epidemiology, 1196–1198

gastroenteritis, 47–55, 1189, 1197–1203

genotypes and genotypes, 1189–1193

genome, 1194–1196

historical aspects, 1189

host range, 1196

immune response, 1199

inactivation by physical and chemical agents, 1196

incidence and prevalence of infection, 1197

laboratory diagnosis, 1201–1202

nosocomial infections, 1197–1198

nucleic acid detection, 1201–1202

Downloaded from www.asmscience.org by IP: 54.70.40.11
On: Tue, 23 Jul 2019 13:26:44
Cauterizing agents, for HPV infections, 658

See

CCR5 antagonists, 170

Castleman

Carvedilol, for myocarditis-related heart failure, 107

Cardiovascular disease.

Carbon dioxide laser surgery, for HPV infections, 119, 657, 659, 661

Cantharidin, for herpes zoster, 124

Candidiasis, HIV , 811, 813

CALT.

Capsid-inhibiting compounds, for CMV, 82

Capsid, CMV , 481, 487

Capsaicin, for herpes zoster, 124

Candid #1, 1102

Canarypox virus, 387

California encephalitis virus, 1059

Calicivirus vaccine, 1203

Canine croup, 874

Candid #1, 1102–1103

Candidiasis, HIV, 811, 813

Canine croup, 874

Cantagalo virus, 388

Cantharidin

for HPV infections, 119, 657, 659–660 for molluscus contagiosum, 407

Capsaicin, for herpes zoster, 124

Capsid, CMV, 481, 486–487

Capsid-inhibiting compounds, for enterovirus, 1132–1133

Captopril, for myocarditis-related heart failure, 107

Carbon dioxide laser surgery, for HPV infections, 658–659, 661

Cardiomyopathy. See Dilated cardiomyopathy

Cardiovascular disease. See Heart disease

Carey Island virus, 1269

CAR receptor, 576–578, 583

Carvedilol, for myocarditis-related heart failure, 107

Castleman’s disease. See Multicentric Castleman’s disease

Cauterizing agents, for HPV infections, 658

CCHF virus. See Crimean-Congo hemorrhagic fever virus

CCR5, 800–803, 807

CCR5 antagonists, 170–175

CD4+ T cells


CD8+ lymphotropism, HTLV, 781

CD8+ T cells

antigen recognition, 336–337 cytotoxic, 338 HIV-specific, 809–810

immunologic basis of vaccination, 357 triggering of, 333–334 CD46, 905–906 CD81, 1318–1319, 1334 CD115, 1116, 1120–1121 CDRs. See Complementarity-determining regions CEE virus. See Central European encephalitis virus Celiac disease, rotavirus and, 407 Cervical intraepithelial neoplasia (CIN), 659-661 Cervical cancer

Cervarix, 119, 353, 361, 653–655

Cervical cancer

HIV, 813


CMV infection, 489, 493–494 croup, 13 EBV, 532–533
gastroenteritis, 49–52, 54
HAV, 1177–1178
HCV, 1327
HIV, 814, 817
influenza virus, 1028
measles virus, 908–909
metapneumovirus, 875–877, 883
myocarditis, 102–103, 106
parainfluenza virus, 875–877, 883
pneumonia, 19–20
respiratory disease, 9–10
RSV, 875–877, 881–882
ChimeriVax-JE, 1280
Chlorpheniramine, for common cold, 11
Cholera virus, 1065
Chronic active EBV (CAEBV), 534
Chronic fatigue syndrome
clinical assessment, 376–378
diagnostic criteria, 373
epidemiology, 373
etiology, 373
genetic predisposition, 376–378
immunologic disturbance, 374–377
infectious, 372, 374, 377
metabolic or neuroendocrine disturbance, 375–377
psychological disturbance, 372, 375, 377
HIV/AIDS, 1051
historical perspective, 371–372
laboratory assessment, 376–378
natural history, 373
treatment, 378–379
Chronic keratoconjunctivitis (CKC), 160
Chronic wasting disease, deer and elk, 1425, 1428, 1430–1431
Chuzan virus, 842
cIAPs. See Cellular inhibitory of apoptosis protein
Cidofovir
for adenovirus infections, 590
adverse effects, 219, 228
for BK virus infections, 88, 616
clinical applications, 228–229
for CMV infections, 81–82, 125, 158, 218, 228
dosing regimen, 218
drug interactions, 219, 228
for herpesvirus infections, 216–219, 228–229
for HHV-6 infections, 86, 517
for HHV-7 infections, 517
for HHV-8 infections, 87, 126
for HPV infections, 660
for HSV infections, 228–229, 437
for KSHV, 564
mechanism of action, 228
pharmacokinetics, 219, 228
for PML, 615
for pneumonia, 23–24
resistance, 228
for smallpox vaccine complications, 407–408
spectrum of activity, 228
structure, 216
susceptibility testing, 296
for vaccinia virus, 162
Ciluprevir, 1333
Cimetidine, for HPV infections, 660
CIN. See Cervical intraepithelial neoplasia
Circumcision, HIV prevention, 819
Citrhosis
HBV, 728–730, 736
HCV, 1327–1328
HDV, 1414–1415
HEV, 1216
CJD. See Creutzfeldt-Jakob disease
CKC. See Chronic keratoconjunctivitis
Class switch recombination (CSR), 342–343
Clemastine, for common cold, 11
Clevudine, for HBV, 741–742
CLIA. See Chemiluminescent immunoassay
Clinical virology, 1
Clothing factor disorders, 1177
CLR. See C-type lectin receptors
CMIA. See Chemiluminescent microenzyme immunoassay
CMV. See Cytomegalovirus
CMV PepVax, 82
CMX-001. See Brincidofovir
CNS infections. See Central nervous system infections
Cobasticir
adverse effects, 201
clinical applications, 170, 201
dosing regimen, 170
drug interactions, 201
fixed-dose combination, 197
for HIV, 170, 200–201
pharmacology, 200–201
resistance, 201
structure, 200
Cold. See Common cold
Cold-blade surgery, for HPV infections, 658, 660
Cold sore susceptibility gene (CSSG-1), 419
Cold vaccine, 1156–1157
Collitis, adenovirus, 583
Colorado tick fever virus (CTFV)
biochemistry, 843–844
classification and taxonomy, 3, 841–842
clinical manifestations, 846–847
CNS infections, 312–313
CMV, 125, 163, 488–489, 493–494, 503–504
diagnosis, 312–313
prevention, 11
ECM, 503–504
HSV, 523
CMV, 487
Coma, therapeutic, for rabies, 974–976
Commensal organisms, barrier immunity, 324
Common cold
clinical manifestations, 746–747
classification and taxonomy, 841
virology, 841
virion composition, 843
treatment, 847
skin lesions, 846
serodiagnosis, 307
genome, 841, 843
clinical manifestations, 846
in pregnancy, 846
diagnosis, 312–313
historical aspects, 841
hemorrhagic diatheses, 845
organ and cellular pathology, 845
historical aspects, 841
immune response, 845–846
 immunoassay, 298
laboratory diagnosis, 846–847
neurologic disorders, 846
organ and cellular pathology, 845
pathogenesis, 845–546
PCR methods, 847
in pregnancy, 846
prevention, 847
proteins, 843–844
serodiagnosis, 307
skin lesions, 846
virology, 841–843
Colorado tick fever virus (CTFV)
vaccine, 847
Colposcopy, 647–648, 649–650
Coltivirus
biochemistry, 843–844
classification and taxonomy, 841–842
clinical manifestations, 846–847
differential diagnosis, 846–847
distribution and geography, 843–844
ecology, 843–845
epidemiology, 843–845
genome, 841, 843–844
historical aspects, 841
immune response, 845–846
laboratory diagnosis, 846–847
organ and cellular pathology, 845
pathogenesis, 845–846
prevention, 847
proteins, 843–844
treatment, 847–849
virion composition, 843–844
Coma, therapeutic, for rabies, 974–976
Central nervous system (CNS) infections
etiology, 373
epidemiology, 373
differential diagnosis, 10–11
etiology, 10–11
influenza virus, 1026, 1028
pathogenesis, 11
prevention, 11–12
rhinovirus. See Rhinovirus
syndrome definition, 9–10
treatment, 11–12
Common cold vaccine, 1156–1157
Common warts, 646
Complementarity-determining regions (CDRs), 336–337
Complement fixation, 309
Complement system, 328
Complera, 197
Condyloma acuminata. See Anogenital warts
Congenital infection
CMV, 125, 163, 488–489, 493–494, 503–504
diagnosis, 312–313
EBV, 532
HSV, 428
Congenital ocular disease, 163
Congenital rubella syndrome (CRS), 163, 1381, 1383
clinical manifestations, 1387–1388
diagnosis, 1388
epidemiology, 1384
histopathology, 1385
immune response, 1385–1386
prevention, 1388–1389
treatment, 1389–1390
Congenital varicella syndrome, 470, 472
Congestive heart failure, 101–102
Congenital active EBV (CAEBV), 534
Complera, 197
Coronavirus (CoV)
animal hosts, 1243, 1247
asthma and, 1254
biology, 1245–1248
bronchiolitis, 12, 1254
cell culture, 1247–1248
classification and taxonomy, 4, 1243–1244
clinical manifestations, 1253–1255
CNS infections, 1254
Coronavirus (CoV) (continued)
  common cold, 10, 1243, 1253–1254
croup, 10, 13, 1254
cytopathic effect, 1247–1248
distribution and geography, 1248
demic, 1243, 1247–1250, 1252–1254
dermic, 1244–1245, 1247–1249,
1251–1252, 1255
epidemiology, 1248–1252
experimental animal models, 1247
gastroenteritis, 52–53, 1244–1245,
1247–1249, 1255
genome, 1245–1246
histopathology, 1252
historical aspects, 1243
host range, 1247
immune response, 1253
immunocompromised individual, 1254
inactivation by physical and chemical
agents, 1248
incidence and prevalence of infection, 1248–1250
laboratory diagnosis, 1255
incidence and prevalence of infection, 1254
inactivation by physical and chemical
agents, 1248
immunocompromised individual, 1254
inactivation by physical and chemical
agents, 1248
infection control, 1256
proteins, 1243–1246
replication, 1245–1247, 1252
respiratory disease, 1243, 1248–1250,
1252–1257. See also Severe acute
respiratory syndrome coronavirus
risk factors, 1251–1252
seasonality, 1249
serodiagnosis, 1256
transmission, 1249–1251
transplant recipient, 1245
treatment, 1257
virion composition, 1244–1245
virion structure, 1244–1245
virology, 1243–1248
Coronavirus-like particles (CVLPs), 1244,
1255
Coronavirus (CoV) vaccine, 1256–1257
Corticosteroid therapy
for adult T-cell lymphoma, 786
for bronchiolitis, 17
for chronic fatigue syndrome, 378
for coronavirus, 1257
for croup, 14–15
for EBV-associated disease, 534, 539
for hemorrhagic fever, 147
for HSV, 156–157
for HTLV-associated myelopathy, 787
for infectious mononucleosis, 534
for metapneumovirus infections, 890
for myocarditis, 107
for parainfluenza virus infections, 889
for pneumonia, 22
for RSV, 888
Cottontail rabbit papillomavirus, 625,
635, 642
CoV. See Coronavirus
Cowpox virus, 1269
Cowpox virus (CPXV)
classification and taxonomy, 387–388
clinical diagnosis, 405
clinical manifestations, 388, 402–403
epidemiology, 388, 395–397
host range, 388, 394
immune response, 401
laboratory diagnosis, 405
pathogenesis, 399
structure, 389
transmission, 397–398
Cowpoxvirus
acute flaccid paralysis, 1125
cell culture, 292, 1130
coronal fatigue syndrome, 372
classification and taxonomy, 1113–1114
CNS infections, 33–34, 39
conjunctivitis, 1128
epidemiology, 1118–1120
gastroenteritis, 1129
gastrointestinal disease, 47–48
genome, 1115–1116
hand-foot-and-mouth disease,
1127–1128
herpangina, 12, 128–129, 1127
histopathology, 1122
historical aspects, 1113
immune response, 1122
isolation, 1130
laboratory diagnosis, 1130–1131
meningitis, 1123–1124
myocarditis, 99–103, 105–106, 1129
neonatal infections, 1125–1127
neurologic disease, 1123–1124
non-specific febrile illnesses of infancy,
1126
ocular manifestations, 160–161
pathogenesis, 1120–1122
pharyngitis, 12
pleurodynia, 1128
pneumonia, 1126–1127
prevention, 1131–1132
replication, 1116–1118
serodiagnosis, 307
skull lesion, 115–116, 128–129
transmission, 1132–1133
troism, 1120–1121
virion structure, 1114–1115
virology, 1113–1118
Cowpoxvirus vaccine, 1132
CPE. See Cytopathic effect
CPX. See Cowpox virus
Creutzfeldt-Jakob disease (CJD), 39–42,
1425
animal models, 1426
antigen detection, 1436
brain MRI, 1435–1436
cerebrospinal fluid analysis, 1434–1435
clinical manifestations, 1426,
1431–1434
complications, 1434
diagnosis, 1434–1436
differential diagnosis, 1437
EEG, 1434
epidemiology, 1428–1430
familial, 1426, 1432–1433
genetic testing, 1436
iatrogenic, 1426, 1429, 1432
passive immunoprophylaxis, 1439
pathogenesis, 1430–1431
prevention, 1437–1439
prion biology, 1427–1431
specimen collection and handling,
1439
sporadic, 1426, 1428–1429, 1431–1437
treatment, 1439
variant, 1425–1426, 1428–1438
Crimean-Congo hemorrhagic fever (CCHF)
virus, 3, 1059–1060, 1063
clinical manifestations, 145, 1078–1079
distribution and geography, 1077–1078
epidemiology, 142–144, 1077–1078
laboratory diagnosis, 1079
myocarditis, 100
pathogenesis, 144–145, 1077
prevention, 148, 1079–1080
treatment, 147, 1080
Crimean-Congo hemorrhagic fever (CCHF)
virus vaccine, 1079
Croup
clinical manifestations and syndrome
definition, 13
coronavirus, 1254
etiology and differential diagnosis, 10,
13–14
influenza virus, 1027–1029
measles virus, 916
metapneumovirus, 883
parainfluenza virus, 873, 878, 883, 888–889
pathogenesis, 144–145, 1077
prevention, 148, 1079–1080
CNS. See Congenital rubella syndrome
Cryotherapy, for HPV infections, 657
Cytokines, 325–328
in adaptive immune response, 337–339
class switch recombination, 343
in induced innate immune response,
331–332
pyrogenic, 332
Cytolytic CD4+ T cells, 340
Cytomegalovirus (CMV)
acyclovir for, 78, 220, 499–502
antigenea, 496
antiviral agents for. See Antiv herpesvirus
agents
antiviral resistance, 497, 504
antiviral susceptibility testing, 295–296
biology, 487–488
brincidofovir for, 81, 230, 502–503
bronchiolitis obliterans, 78
cell culture, 292–294, 496–497
chronic fatigue syndrome, 372
cidofovir for, 81–82, 125, 158, 218, 228
classification and taxonomy, 481
clinical manifestations, 300, 493–495
CNS infections, 32, 36, 38, 42
composition
capsid, 481
envelope, 482–483
protein pp65, 481–482
for HIV, 170, 176, 178, 182–183
postexposure prophylaxis, 819
preexposure prophylaxis, 818
mechanism of action, 182
pharmacokinetics, 176
pharmacology, 182
resistance, 182
structure, 178, 241
Emus
eastern equine encephalitis virus, 1357
western equine encephalitis virus, 1360
Enalapril, for myocarditis-related heart failure, 107
Encephalitis
adenovirus, 583, 587
alphavirus, 1347–1351
approach to patient, 42–43
astrovirus, 1231, 1236–1238
BK virus, 614
bornavirus, 1396, 1400
bunyavirus, 1064
clinical manifestations, 40
CMV, 492, 494–495
definition, 31
diagnosis, 40–42
enterovirus, 1119–1120, 1122, 1124–1125
epidemiology, 32–34, 38–39
etiology, 32–34
flavivirus, 1267, 1273–1291
Hendra virus, 950, 956
HHV-6, 515
HHV-6in, 86
HHV-7, 515
HSV, 121, 415, 420, 424, 429, 430–431, 436
human bocavirus, 688
influenza virus, 1030
Japanese encephalitis virus, 1277–1278
laboratory findings, 32–34, 40–41
measles virus, 129
mumps virus, 934–936, 939
Murray Valley encephalitis virus, 1279
Nipah virus, 957, 954, 957–958
parvovirus B19, 688
pathogenesis, 32–34, 39–40
Poxvirus, 1280
prevalence, 38–39
prevention, 41–42
rabies virus, 967, 970, 971–972
rubella virus, 1387, 1390
St. Louis encephalitis virus, 1283
tick-borne. See Tick-borne encephalitis virus
treatment, 42
VZV, 468, 470
West Nile virus, 1290
Encephalopathy, 31
influenza virus, 1027
Enecepur, 1287
EnceVir, 1287
Endocardial fibroelastosis (EFE), 99, 103
Endocardi
current adverse effects, 190–191
cutaneous adverse effects, 134
dosing regimen, 170
drug interactions, 190–191
fixed-dose combination, 197
for HIV infections, 170, 189–191
pharmacokinetics, 190
pharmacology, 191
resistance, 191
structure, 189
Emerging disease
diagnosis, 305–306
vaccines against, 365
zoontic paramyxoviruses, 949–953
Emerging viral pathogens, 1
Emtricitabine
adverse effects, 176, 182, 240
clinical applications, 170, 182–183, 240
Cutaneous adverse effects, 134
dosing regimen, 170, 240
drug interactions, 176, 182
fixed-dose combination, 197
for HBV, 239–240, 741
for HIV, 170, 176, 178, 182–183
postexposure prophylaxis, 819
preexposure prophylaxis, 818
mechanism of action, 182
pharmacokinetics, 176
pharmacology, 182
resistance, 182
structure, 178, 241
EnerXis-B, 353, 359, 361
Enfuvirtide
adverse effects, 169–171
structure, 174
Entebbe bat virus, 1269
Entecavir
adverse effects, 240, 242
clinical applications, 242
for HBV, 239–240, 741
dosing regimen, 240
for HBV, 62, 242, 736, 740–741, 748
for HDV infections, 1417
mechanism of action, 242
pharmacology, 242
resistance, 242, 739, 744–745
spectrum of activity, 242
structure, 241
Entertically transmitted hepatitis, 62–64
Enteric virome, HIV alterations in, 324
Enteroxovirus (EV)
cell culture, 292–294
chronic dilated cardiomyopathy, 1129
chronic fatigue syndrome, 378
classification and taxonomy, 1113–1114
clinical manifestations
cardiovascular illnesses, 1129
gastrointestinal illnesses, 1129
muscular syndromes, 1128
neonatal infection, 1125–1127
neurolologic illnesses, 1122–1125
possible associated diseases, 1129–1130
syndromes involving mucous membranes and integumentary system, 1127–1128
CNS infections, 31–34, 36–39, 41
common cold, 10
conjunctivitis, 1128
cytopathic effect, 1118
diabetes and, 1129–1130
diagnosis, 305–306
encephalitis, 1119–1120, 1122, 1124–1125
epidemiology, 1118–1120
gastroenteritis, 1113, 1129
gastrointestinal disease, 48
genome, 1115–1116
hand-foot-and-mouth disease, 1127–1128
herpangina, 128–129, 1127
histopathology, 1122
historical aspects, 1113
immune response, 1122
immunocompromised individual, 1125
inflammatory myositis, 1128
isolation, 1130
laboratory diagnosis, 1130–1131
meningitis, 1119–1124
neonatal infections, 1133
nonspecific febrile illnesses of infancy, 1126
nucleic acid detection, 1130
ocular manifestations, 153, 157, 160–161
pathogenesis, 1120–1122
PCR methods, 1130
pharyngitis, 10, 12
pleurodynia, 1128
pneumonia, 10, 19, 1126–1127
prevention, 1131–1132
replication, 1116–1118
respiratory disease, 1126–1127
seasonal patterns, 9, 11
seizures, 1125
sepsis, 1125–1126
serodiagnosis, 307, 310, 1130–1131
skin lesions, 128–129, 1127–1128
treatment...
transplant recipient, 1327–1328
treatment
indictions for, 1330
interferon, 244, 247–248, 1330–1331
liver transplant, 1328
tropism, 1318
virology, 1318–1319
wiring composition, 1314–1315
virologists, 1314–1315
virology, 1313–1321
Hepatitis C virus (HCV) vaccine, 1329
Hepatitis D virus (HDV)
clear hepatitis, 1414
treatment, 1414–1416
viral drugs, 1417
chronic hepatitis, 1414–1415
cirrhosis, 1414–1415
clinical manifestations, 62, 67, 1414–1415
distribution and geography, 1412–1413
epidemiology, 62, 64–65, 1413–1414
fulminant hepatitis, 1412
genotypes, 1409–1410
HDV-HBV coinfection, 63–64, 68, 1409–1412, 1414
HDV-HCV coinfection, 1415
hepatocellular carcinoma, 1415
historical aspects, 1409
historical perspectives, 61–63
HIV-HDV coinfection, 1415
immune response, 1412–1413
laboratory diagnosis, 1415–1416
nucleic acid detection, 1416
pathogenesis, 1412–1413
pathophysiology, 65–66
PCR methods, 1415
prevalence of infection, 1413–1414
prevention, 1416
proteins, 1410
replication, 1409–1411
ribozyme, 1409–1410
risk factors, 1413
serodiagnosis, 307, 1416
serologic features, 67–68
taxonomy, 4
transmission, 1414
virology, 1409–1412
Hepatitis D virus (HDV) vaccine, 1416
Hepatitis E virus (HEV)
acute, 1216–1217
treatment, 1220
age-specific attack rate, 1212–1213
animal models, 1215
antigen detection, 1219
avian, 1209–1210
biology, 1210–1212
cell culture, 1210–1211
chronic, 1216–1217
treatment, 1220–1221
classical, 1212
clinical diagnosis, 1219–1220
clinical manifestations, 62, 66–67, 1216–1217
complications, 1217–1219
correlates of immune protection, 1216
diagnostic algorithm, 1219–1220
distribution and geography, 1212–1214
epidemic patterns, 1212
epidemiology, 62–64, 1212–1215
fulminant hepatitis, 1216–1217
genome, 1209–1210
genotypes, 1209–1210
Guillain-Barré syndrome and, 1218
historical aspects, 1209
historical perspectives, 61–63
host range, 1212
immune response, 1215–1216
immunocompromised individual, 1219–1220
inactiviation by physical and chemical
agents, 1211–1212
incidence and prevalence of infection, 1214–1215
incubation period, 1216, 1219
laboratory diagnosis, 1219–1220
mammalian strains, 1209–1210
neurologic disease, 1218
nosocomial infections, 1217
nucleic acid detection, 1219
pathogenesis, 1215
pathophysiology, 65–66
PCR methods, 1219
in pregnancy, 1209, 1216–1217, 1221–1222
prevention
active immunization, 1221–1222
blood supply, 1222
risk reduction, 1221
proteins, 1209–1210
reinfections, 1212
replication, 1210–1211, 1215
risk factors, 1212
serodiagnosis, 307, 1219
serologic features, 67–68
PCR methods, 1219
in transplant recipient, 1216, 1220–1221
travelers, 1209, 1212
transmission, 1220–1221
virology, 1209–1212
zoonotic, 1212
Hepatitis E virus (HEV) vaccine, 361, 365, 1221–1222
Hepatocellular carcinoma (HCC)
HBV, 61–62, 69, 713, 721, 730
HCV, 63, 69, 1328
HDV, 1415
Hepevirus, taxonomy, 4
Herd immunity, vaccination, 352
Herapangina
coxsackievirus, 12, 128–129
enterovirus, 128–129, 1127
Herpes gladiatorum, 121, 430
Herpes simplex virus (HSV)
acyclovir for, 87, 122, 157, 215, 217, 220, 435–437
antiviral agents for. See Antiherpesvirus agents
antiviral resistance, 436–437
antiviral susceptibility testing, 295–296
antiviral toxicity, 436–437
brivudine for, 217, 222–223
bronnchitis, 10
cell culture, 292–294, 432
cidofovir for, 228–229, 437
classification, 416
clinical manifestations, 300, 426–431
CNS infections, 32, 34–36, 38–42, 430–431
genital infection, 163
cytologic examination, 432
cytopathology, 298–300
diagnosis, 116, 291, 305, 306
treatment, 421, 422, 424, 429
epidemiology
outbreaks, 421
prevalence, 420–422
recurrances, 421–422
erythema multiforme, 116, 121–122, 415, 436
exogenous reinfection, 423
famiclovir for, 122, 157, 217, 221–222, 435–436
foscarnet for, 87, 122, 218, 226–228, 437
ganciclovir for, 223–225
gene therapy, 434–435
genetic susceptibility, 431
Hepatitis A virus (HAV) vaccine, 1327–1328
neonatal infections, 415, 424–426
treatment, 435–436
genome, 416, 419
noroviruses, 415, 424–426
hepatitis, 70, 428, 436
historical aspects, 415
HIV-HSV coinfection, 132, 422, 430
host range, 415
immune response, 326–327, 336, 415, 418, 424–426
immunosuppression, 297–298
immunocompromised individual, 415, 424, 430, 435–436
intrauterine infections, 428
keratitis, 152–157, 424
keratoconjunctivitis, 415, 430
keratitis, 415, 418–420, 424
lacracy, 415, 418–420, 424
meningitis, 121, 427, 431
meningoencephalitis, 427
mononucleosis syndrome, 426
myocarditis, 100, 106
neonatal infections, 415, 424–426
clinical presentation, 428
disseminated, 428–429
encephalitis, 429
contagion, 432
prognosis, 430
skin, eye, mouth infection, 429–430
neuromorbillence, 420
nosocomial infections, 432
ocular manifestations, 152–157, 163
opharyngeal infections, 121, 420–421, 424, 426–427
treatment, 435, 437
pathogenesis, 420, 422–426
PCR methods, 420, 422–426
pathology, 422–423
correlation of infection, 157, 424
penciclovir for, 217, 221–222
pharyngitis, 10, 12
pneumonia, 10, 21, 23
in pregnancy, 422, 428
prophylaxis, 432
primary infection, 424–425, 426–427
pritelivir for, 437
proteins, 416
radiculomyelitis, 427, 431
Herpes simplex virus (HSV) (continued)
-reactivation, 419–420, 424–425
-recurrent infection, 425–428
-replication, 415
-dephosphorylation of eukaryotic initiation factor 2a, 418
-initiation, 416–417
-pathogenic correlates, 420
-postentry events, 416–418
-regulation, 419–420
-replicative functions and host innate immune response, 418
-serodiagnosis, 307, 311, 312, 432
-sites of infection, 424
-diagnosis, 121–122
-epidemiology and clinical manifestations, 121–122
-treatment and prevention, 122
-tracheobronchitis, 10, 18
-transplant recipient, 76, 87, 430
-treatment, 435–437
-trifluridine for, 217, 223
-valacyclovir for, 122, 157, 217, 221, 433–436
-vidarabine for, 437
-virus structure, 416
-HPV.
-See also specific herpesviruses
-ocular manifestations, 153, 155–159
-skin lesions, 115–116
-taxonomy, 2
-Herpesvirus simiae. See Cercopithecine herpesvirus 1
-Herpes zoster
-active immunization against, 473
-clinical diagnosis, 469–470
-clinical manifestations, 469
-complications, 470
-diagnosis, 123
-epidemiology and clinical manifestations, 122–123
-historical aspects, 459
-incidence and prevalence, 464
-laboratory diagnosis, 471
-mortality from, 464
-passive immunization against, 472
-pathogenesis, 466–467
-prevention, 471–475
-skin lesions, 469
-transmission, 464–465
-transplant recipient, 464
-treatment, 474–475
-treatment and prevention, 124
-visceral, 470
-Herpes zoster ophthalmicus (HZO), 158–159
-Herpes zoster vaccine, 354
-Herpeti chiroptera, 121–122, 430, 436
-HEv. See Hendra virus
-HF severe fever. See Hendra virus
-HFMID. See Hand-foot-and-mouth disease
-HFRS. See Hemorrhagic fever with renal syndrome
-HGG. See Hypogammaglobulinemia
-HGS101, 172
-HHV-6. See Human herpesvirus 6
-HHV-7. See Human herpesvirus 7
-HHV-8. See Kaposis sarcoma-associated herpesvirus
-Highlands J virus (HJV), 1348–1349
-Histamine, 326
-Histocompatibility-blood group antigen (HLA) receptors, 52
-Histopathology, diagnostic, 299–300
-HIV. See Human immunodeficiency virus
-HIV-associated nephropathy, 813
-HIV-associated neurologic dysfunction (HAND), 811–812
-HIV PRT GenChip, 297
-HJV. See Highlands J virus
-HLA associations. See Human leukocyte antigen associations
-HLA genes, 334
-HLH. See Hemophagocytic lymphohistiocytosis
-Hodgkin’s disease
-EBV, 82, 124, 537
-HHV-6, 515
-Homeopathy, for HIV infections, 661
-Horses
-alphavirus, 1347, 1353
-borna virus, 1397, 1401–1402
-eastern equine encephalitis virus, 1363–1364
-Hendra virus, 950, 953–954, 960
-influenza virus, 1014–1015
-Nipah virus, 950
-Venezuelan equine encephalitis virus, 1363–1364
-western equine encephalitis virus, 1360
-HPV. See Human papillomavirus
-HSR. See Hypersensitivity reaction
-HSV. See Herpes simplex virus
-HSV1716, 434
-HTLV. See Human T-cell lymphotropic virus
-HTLV-1.
-Human T-cell lymphotropic virus
-HTLV-1.

-Human herpesvirus 6 (HHV-6)
-acute infection, 514–515
-acyclovir for, 86, 215, 517
-antigen detection, 517
-biology, 513
-cancer and, 515
-cell culture, 293, 513, 516
-chronic fatigue syndrome, 372, 374, 378, 515
-cidofovir for, 517
-classification and taxonomy, 2, 511
-clinical manifestations, 514–516
-cytopathic effect, 513
-DNA detection, 516
-drug-induced hypersensitivity syndrome, 515–516
-encephalitis, 32, 86, 515
-epidemiology, 513–514
-exanthem subitum, 125, 511, 514–515
-foscarnet for, 86, 218, 226–227, 517
-ganciclovir for, 86, 223–225, 517
-genome and genetic properties, 511–512
-historical aspects, 511
-HHV-6 infection, 514
-isolation, 516
-laboratory diagnosis, 516–517
-latency, 515–516
-lymphadenitis, 515
-multiple sclerosis, 515
-myocarditis, 1357–1360
-ocular manifestations, 153, 155, 159
-pathogenesis, 514
-PCR methods, 516
-prevention, 517
-proteins, 512–513
-reactivation, 515–516
-seizures related to, 515
-serodiagnosis, 307, 312, 517
-seroprevalence, 513–514
-skin lesions, 115–116, 511, 514–515
-diagnosis, 126
-epidemiology and clinical manifestations, 125–126
-treatment, 516
-transmission, 514
-transplant recipient, 75–76, 85–86, 515
-treatment, 517
-variants, 511
-virology, 511–513
-Human herpesvirus 7 (HHV-7)
-acute infection, 514–515
-biology, 513
-cell culture, 293, 516
-chronic fatigue syndrome, 372
-cidofovir for, 517
-classification and taxonomy, 2, 511
-clinical manifestations, 514–516
-DNA detection, 516
-encephalitis, 515
-epidemiology, 513–514
-foscarnet for, 517
-ganciclovir for, 517
-genome and genetic properties, 511–512
-historical aspects, 511
-isolation, 516
-laboratory diagnosis, 516–517
-latency, 515–516
-pathogenesis, 514
-PCR methods, 516
-pitravir, 516
-prevention, 517
-proteins, 512–513
-reactivation, 515–516
seizures related to, 515
serodiagnosis, 307, 312, 517
seroprevalence, 513–514
skin lesions, 115–116, 511, 514–515
diagnosis, 126
epidemiology and clinical manifestations, 125–126
treatment, 126
transmission, 514
transplant recipient, 85–86, 515
treatment, 517
virology, 511–513
Human herpesvirus 8. See Kaposi’s sarcoma-associated herpesvirus
Human immunodeficiency virus (HIV) accessory genes, 799–800
antibodies, 797
antigen detection, 814–815
antigenicity, 795–797
asymptomatic period, 807
barrier immunity, 324
biology, 800–803
cancer and, 813
candidiasis, 811, 813
cell culture, 292
in children, 814, 817
circulating recombinant form, 796
classification and taxonomy, 3, 795–797
diagnosis, 814
clinical manifestations, 811–814
CNS disease, 33–34, 42, 810–812
cure challenges, 824
cytopathic effect, 802–803
diagnosis, 306
distribution and geography, 803
diordine disorders, 812
Env proteins, 797–800, 802–803, 809–810
epidemiology, 803–804
foscamet for, 218, 226–227
Gag proteins, 797–799, 802
gastroenteritis, 52, 811–812
genome, 797–799
genotypes, 795–797
gp120, 797–801, 810
heart disease, 813–814
hematologic disorders, 813
hepatitis in, 70–71
histopathology, 808
historical aspects, 795
HIV-2, 795–796, 816–817
HIV-adenovirus coinfection, 583, 587
HIV-EBV coinfection, 132, 536
HIV-HBV coinfection, 722, 734, 736–737
HIV-HCV coinfection, 132, 154,
157–158, 489, 491–495, 1322, 1327
treatment, 503
HIV-HDV coinfection, 1415
HIV-HIV-6 coinfection, 514
HIV-HPV coinfection, 132, 639, 813
HIV-HSV coinfection, 132, 422, 430
HIV-HTLV-I coinfection, 785
HIV-influenza virus coinfection,
1028–1029, 1034
HIV-KSHV coinfection, 549, 556–560, 563–565, 813
HIV-mesV virus coinfection, 909, 915, 920–921
HIV-VZV coinfection, 132, 468–470, 472–473
host range, 802–803
immunoadsays, 816–817
inactivation by physical and chemical agents, 803
incidence and prevalence of infection, 804
incubation period, 804–805
isolation, 814
laboratory diagnosis, 814–818
lymphadenopathy, 811–812
meningitis, 812
metabolic disorders, 812
molluscum contagiosum in, 119–120, 132
mortality, 821
myocarditis, 100
Nef protein, 799–800, 802
neonatal infections, 817
nephropathy, 813
neurologic disease, 810–812
nosocomial infections, 804
nucleic acid detection
PCR methods, 814–815
plasma RNA, 815–816
provincial DNA, 814–815
sample collection, 816
ocular manifestations, 153–155
opportunistic infections, 805, 813–814, 821
oral pathology, 811–812
organ and cell specificity, 805–806
pathogenesis, 804–815
pharyngitis, 12
PML in. See Progressive multifocal leukoencephalopathy
pneumonia, 813, 884
pneumonitis, 812
Pol proteins, 797–799, 802
in pregnancy, 804, 820
prevention
active immunization, 820–821
male circumcision, 819
passive immunoprophylaxis, 819
postexposure prophylaxis, 819
preexposure prophylaxis, 818–819
treatment as, 819–822
primary infection, 806–807, 811–812, 816
progression to AIDS, 807–810, 812
proteins, 797–802, 802–803
receptors, 800–803, 807
replication, 800–802, 805–807
drug targets, 169, 171
reverse transcription, 798, 800–802
Rev protein, 798–799, 802
rheumatologic syndrome, 813
screening for, 814
serodiagnosis, 307–311, 816–817
serotypes, 795–797
skin lesions, 117, 811–812, 813
clinical manifestations, 130–134
diagnosis, 134
epidemiology, 134
systemic and organ-specific manifestations, 812–814
Tat protein, 798–799, 802
time course of infection, 806–807
transcription and gene expression, 800–802
transmission, 804, 818–821
treatment, 821
antiretroviral therapy. See Antiretroviral agents
as prevention, 819–820
tropism, 802–803, 811
tuberculosis and, 813
unique recombinant forms, 796
vaccine development, 343, 352
Vif protein, 799–800, 802
viral load, 807–809
virology, 511–513
Vpr protein, 799–800, 802
Vpu protein, 799–800, 802
Vpx protein, 799–800
wasting disease, 812–813
Western blot, 816
yellow fever virus vaccine in, 1301
Human immunodeficiency virus (HIV) vaccine, 820–821
Human leucocyte antigen (HLA) associations
HSV infections, 431
HTLV infections, 781
Human/Murine rotavirus, 842
Human papillomavirus, 118, 648, 660
Human papillomavirus (HPV) animal models, 635
anogenital disease. See Anogenital disease
basal cell carcinoma, 640
biology, 633–635
cancer and, 639–643
cell culture, 635
cell transformation, 642–643
cervical cancer, 625, 627, 635, 813
diagnosis, 637–638
epidemiology, 642–643
risk factors, 639–640
classification, 626
clinical manifestations, 300, 627, 646–649
genital, 665
cytology, 645, 649–650
cytopathology, 299–300
diagnosis, 116
distribution and geography, 635–637
duration of infectivity, 641
diagnosis, 635–638
epidermodysplasia verruciformis, 625, 627, 638, 640, 646–647, 653, 659
focal epithelial hyperplasia, 627, 635, 638, 659
genome, 628–629
genotypes, 626–627
histopathology, 643–645, 649–650
historical aspects of, 625–626
HIV-HPV coinfection, 639, 813
in HIV patient, 132
host range, 635
immune response, 336, 644–646
immunocompromised individual, 637–640, 646, 653
immunocytotoxicity, 650–651
inactivation by physical and chemical agents, 635
incidence and prevalence of infection, 637
laboratory diagnosis, 649–652
latency, 641–643
neonatal infections, 637, 655
non-melanoma skin cancer, 640
nosocomial infections, 641
Human papillomavirus (HPV) (continued)
  nucleic acid detection, 651–652
  ocular manifestations, 153, 162
  oral cavity lesions, 648, 663
  oropharyngeal cancer, 640
  Pap smear, 299
  pathogenesis, 641–646
  PCR methods, 649, 651–652
  in pregnancy, 655
  prevention, 651
  active immunization, 653–655
  chemoprophylaxis, 653
  passive immunoprophylaxis, 653
  proteins, 628–634
  recurrent respiratory papillomatosis, 625, 627, 638–641, 648, 653, 658–659, 663
  infections, 640
  replication, 633–635, 641
  risk factors, 638–641
  serodiagnosis, 649, 651
  serotypes, 627
  skin lesions, 115–117, 321–323
  clinical manifestations, 118
  diagnosis, 118–119
  epidemiology, 117–118
  prevention, 119
  treatment, 119
  squamous cell carcinoma, 118–119, 625, 639–640, 648–649
  taxonomy, 2, 626–627
  transmission, 640–641
  transplant recipient, 638–640
  treatment, 651–663
  approaches, 661
    chemical methods, 657–660
    patient education, 662–663
    physical methods, 660
    suggestions, hypnosis, homeopathy, 661
    therapeutic vaccine, 661
  virology, 655–657
  warts. See Warts
  therapeutic, 661
Human parvovirus. See Parvovirus
Human polyomavirus 6, 600, 606, 608, 614
Human polyomavirus 7, 600, 606, 608, 614
Human polyomavirus 9, 600, 606, 608
Human polyomavirus 12, 600
Human T-cell lymphotropic virus (HTLV) arthritis, 782, 785
  serodiagnosis, 307, 311
  taxonomy, 3
  uveitis, 162, 782–783, 785
Human T-cell lymphotropic virus type 1 (HTLV-I)
  adult T-cell lymphoma. See Adult T-cell lymphoma
  biology, 773
  cellular assays, 782
  cervical cancer, 784
  classification and taxonomy, 771–772
  clinical manifestations, 782–786
  dermatitis, 783, 785–786
  distribution and geography, 774–775
  environmental and socioeconomic cofactors, 778
  epidemiology, 774–778
  genome, 771–773
  HBZ protein, 772–774, 778–779
  historical aspects, 771
  HIV-HTLV coinfection, 785
  HLA associations, 781
  immune response, 779–781
  incidence and prevalence of infection, 776
  infection control measures, 787
  isolation, 782
  laboratory diagnosis, 782–783
  lung cancer, 784
  lymphadenopathy, 783
  myelopathy. See HTLV-associated myelopathy
  pathogenesis, 778–782
  PCR methods, 782
  pneumonitis, 783
  polyomysitis, 783, 785
  in pregnancy, 786
  prevention, 787–788
  proteins, 772–774, 778–779
  proviral load, 779
  pX I and II proteins, 772–774, 778–779
  receptors, 773–774
  replication, 773–774
  reverse transcription, 773–774
  serodiagnosis, 782–783
  Sjögren's syndrome, 783
  strongyloidiasis, 783, 785
  Tax protein, 772–774, 778–779
  transmission, 776–778
  transplant recipient, 777–778
  treatment, 786–787
  tropism, 773–774
  uveitis, 783
  virion composition, 771–773
  virology, 771–774
Human T-cell lymphotropic virus type 2 (HTLV-II)
  biology, 773
  CDR+ lymphotropism, 781
  cellular assays, 782
  classification and taxonomy, 771–772
  clinical manifestations, 782–786
  disease associations, 785
  distribution and geography, 775–776
  environmental and socioeconomic cofactors, 778
  epidemiology, 774–778
  genome, 771–773
  HRZ protein, 772–774, 778–779
  historical aspects, 771
  immune response, 779–781
  incidence and prevalence of infection, 776
  infection control measures, 787
  isolation, 782
  laboratory diagnosis, 782–783
  lymphadenopathy, 783
  myelopathy, 783
  pathogenesis, 778–782
  PCR methods, 782
  pneumonitis, 783
  prevention, 787–788
  proteins, 772–774, 778–779
  proviral load, 779
  pX I and II proteins, 772–774, 778–779
  receptors, 773–774
  replication, 773–774
  reverse transcription, 773–774
  serodiagnosis, 782–783
  Tax protein, 772–774, 778–779
  transmission, 776–778
  transplant recipient, 777–778
  treatment, 786–787
  tropism, 773–774
  uveitis, 783
  virion composition, 771–773
  virology, 771–774
  tropism, 773–774
  virion composition, 771–773
  virology, 771–774
Human T-cell lymphotropic virus type 3 (HTLV-3), 771–772, 774
Human T-cell lymphotropic virus type 4 (HTLV-4), 771–772, 774
Human T-cell lymphotropic virus (HTLV) vaccine, 787–788
Humoral immunity
  antibodies. See Antibodies
  B cells. See B cells
Humoral immunotherapy, for EBV, 85
HV&V-Mix, 294
Hybrid Capture II, 653
Hybridization-based assay, 304–305
Hybrivix assay, 295
Hydrocortisone, for chronic fatigue syndrome, 378
Hydrophobia, rabies, 972
Hydrops fetalis, parvovirus B19, 687, 690
16-α-Hydroxyestrone, for HPV infections, 658
Hypersensitivity reaction (HSR), antitretoviral therapy, 134
Hypnosis, for HPV infections, 661
Hypogammaglobulinemia (HOG), 77
HZO. See Herpes zoster ophthalmicus
Hiz, 473
I
I AHA. See Immune adherence
  hemagglutination assay
Iatrogenic infection
Creutzfeldt-Jakob disease, 1426, 1429, 1432
HCV, 1322–1323
Ibalizumab, 172, 175
IBV. See Infectious bronchitis virus
ICAM-1. See Intercellular adhesion molecule 1
ICP34.5, HSV, 418
Idoxuridine, 215
  for HPV infections, 658
IDX320, 1333
IFA. See Immunofluorescence assay;
  Indirect immunofluorescence
IFNs. See Interferons
Igbo-Ora virus, 1370
IgG antibody assay, CMV, 497
IgM antibody assay, CMV, 497
Igape virus, 1268
IL-28B genotyping, chronic hepatitis B, 726
Ilheus virus, 1269, 1281
Imiquimod
  for condyloma acuminata, 119
  for herpesvirus infections, 229
  for HPV infections, 658–660
  for molluscum contagiosum, 407
Immune adherence hemagglutination assay
  (IAHA), 310
Immune modulation, innate immune response, 356
Immune monitoring
  CMV, 77–78
  EBV, 84
Immune reconstitution inflammatory syndrome (IRIS), 823
Immune-recovery uveitis, 155
Immune response
  adaptive. See Adaptive immunity
  barrier immunity, 321, 323–324, 344
Immunoglobulin

Immunofluorescence assay (IFA),

Immunoassay

Immune stimulating complex, 358

Immunoglobulin A

Immunocompromised individual

Immunochromatographic assay, 311

See also Vaccine

active, 351

schedule of, 360

genetic defects in, 321

basis of vaccination, 354

response to viral infections, 307–308

antigen detection, 1032

antigenic change

antigenic drift, 1016

antigenic shift, 1016–1017

antiviral drugs, 1009, 1040–1042

antiviral resistance, 1040–1042

antiviral susceptibility testing, 295–296

arthritis, 1030

bacterial coinfections, 1024–1026

barrier immunity, 324

biology, 1012–1015

bronchiolitis, 10, 16, 18

bronchitis, 1027–1029

cell culture, 292–294, 1015

in children, 1028

chronic fatigue syndrome, 372

classification, 1009–1010

clinical manifestations, 1016, 1026–1030

CNS infections, 33–34, 38

cold, 10, 1026, 1028

community immunity, 1019

complications, 1027, 1029

conjunctivitis, 1016, 1021

croup, 10, 13, 1027–1029

cytopathic effect, 1022, 1031

diagnosis, 306

diarrhea, 1028

distribution and geography, 1016

in elderly, 1029

encephalitis, 1030

eencephalopathy, 1027

epidemics, 1009, 1018–1020

epidemiology, 1015–1021

geneic engineering, 1012, 1014

gene, 1011–1012

reassortment of gene segments, 1012–1013

historical aspects, 1009–1010

HIV-influenza virus coinfection, 1028–1029, 1034

host genetics, 1025

host range, 1014–1015

immune response, 326, 331, 332, 340, 1025–1026

immunoassay, 297–298

immunocompromised individual, 1029, 1034, 1040

inactivation by physical and chemical agents, 1015

influenza syndrome, 1027–1028

investigational antiviral drugs for, 283–285

isolation, 1031–1032

laboratory diagnosis, 1030–1033

meningitis, 1030

mortality, 9, 1017, 1019–1020

myocarditis, 100, 106, 1030

myositis, 1027–1028

neuraminidase detection, 1032–1033

neurologic disorders, 1028

nosocomial infections, 1019–1020

management, 1033, 1040

ocular manifestations, 153, 162

oseltamivir for, 272, 274, 276–277, 279–281, 1039, 1041–1042

otitis media, 1027–1029

panemics, 1013, 1015–1018

1918 pandemic, 1009–1010, 1017, 1029

parotitis, 1030

pathogenesis, 1022–1026

of symptoms, 1023–1024

viral, 1024
SUBJECT INDEX

INNO-LiPA HIV-1 line probe assay, 296–297
Inotropics, for myocarditis-related heart failure, 107
In situ hybridization, HPV, 651
In situ hybridization (ISH), myocarditis, 105–106
INSTIs. See Integrate strand transfer inhibitors
Integrate strand transfer inhibitors (INSTIs) cutaneous adverse effects, 134 for HIV, 170–171, 189–192 investigational, 172–173, 192
Interleukins, 326
Interferon-α, 328, 331
Interferon-β, 328, 331
Interferon-γ, 331–332
Interferon-λ, 332
Integrase strand transfer inhibitors (INSTIs), in induced innate immune response, 331–332
Interleukins, 326
in adaptive immune response, 337–339 class switch recombination, 343
Intraspecies transmission, 1
Intrauterine infection CMV, 125, 488–489, 493–494 hepatitis, 62, 64–65, 69–70 HSV, 428 parvovirus B19, 687, 690
Intravenous drug use, hepatitis virus transmission, 62, 64–65 Intravenous gamma globulin, for myocarditis, 107
Intussusception adenovirus, 587 astrovirus, 1237 rotavirus, 863–865 lota-carragenan, for common cold, 1157 LPOL, 354 lpratropium, for colds, 1157
lpratropium, for common cold, 12
IRIS. See Immune reconstitution inflammatory syndrome
Irukut virus, 968, 976
ISH. See In situ hybridization
Isla Vista virus, 1065
Israel turkey meningoencephalitis virus, 1269
Ixiota virus, 1060
Jamestown Canyon virus, 1060, 1063–1064 Japanese encephalitis virus, 1267, 1268
arthropod vectors, 1272
barrier immunity, 323
biology, 1275
cell culture, 1272
clinical manifestations, 1277–1278 CNS infections, 33–34, 38, 40–41 diagnosis, 1278 distribution and geography, 1275–1276 epidemiology, 1275–1277 host range, 1272
immune response, 331 incidence and prevalence of infection, 1275
pathogenesis, 1274, 1277 in pregnancy, 1278 prevention, 1278 seasonality, 1277 transmission, 1275–1277 treatment, 1278–1279 virus-specific factors in virulence, 1275
Japanese encephalitis virus vaccine, 353, 1278
Jaundice, hepatitis, 61, 66–67
JC virus (JCV) animal models, 607–608 attachment and entry into cells, 602–603 biology, 602–606 carcinogenesis, 612–613 cell culture, 603, 605
cell transformation, 605 in cerebellar granule neurons, 614 classification and taxon, 2, 599–600 clinical diagnosis, 612–614 clinical manifestations, 613–615 epidemiology, 604, 606–607 historical aspects, 599 host range, 603
immune response, 609 immunocompromised individual, 600 interaction with glial cell cultures, 603, 605
laboratory diagnosis, 615
pathogenesis, 600, 607–613 persistence, 608
PML. See Progressive multifocal leukoencephalopathy in pregnancy, 609 prevention, 615 primary infection, 606 proteins, 601–602 reactivation of persistent infection, 608–609 replication, 603, 608 risk factors, 606–607 serodiagnosis, 615
sites of infection, 600 transmission, 606–607
Jaundice, hepatitis, 61, 66–67
JC virus (JCV) animal models, 607–608 attachment and entry into cells, 602–603 biology, 602–606 carcinogenesis, 612–613 cell culture, 603, 605
cell transformation, 605 in cerebellar granule neurons, 614 classification and taxon, 2, 599–600 clinical diagnosis, 612–614 clinical manifestations, 613–615 epidemiology, 604, 606–607 historical aspects, 599 host range, 603
immune response, 609 immunocompromised individual, 600 interaction with glial cell cultures, 603, 605
laboratory diagnosis, 615
pathogenesis, 600, 607–613 persistence, 608
PML. See Progressive multifocal leukoencephalopathy in pregnancy, 609 prevention, 615 primary infection, 606 proteins, 601–602 reactivation of persistent infection, 608–609 replication, 603, 608 risk factors, 606–607 serodiagnosis, 615
sites of infection, 600 transmission, 606–607
Jamestown Canyon virus, 1060, 1063–1064 Japanese encephalitis virus, 1267, 1268
arthropod vectors, 1272
barrier immunity, 323
biology, 1275
cell culture, 1272
clinical manifestations, 1277–1278 CNS infections, 33–34, 38, 40–41 diagnosis, 1278
distribution and geography, 1275–1276 epidemiology, 1275–1277 host range, 1272
immune response, 331 incidence and prevalence of infection, 1275
pathogenesis, 1274, 1277 in pregnancy, 1278 prevention, 1278 seasonality, 1277 transmission, 1275–1277 treatment, 1278–1279 virus-specific factors in virulence, 1275
Japanese encephalitis virus vaccine, 353, 1278
Jaundice, hepatitis, 61, 66–67
JC virus (JCV) animal models, 607–608 attachment and entry into cells, 602–603 biology, 602–606 carcinogenesis, 612–613 cell culture, 603, 605
cell transformation, 605 in cerebellar granule neurons, 614 classification and taxon, 2, 599–600 clinical diagnosis, 612–614 clinical manifestations, 613–615 epidemiology, 604, 606–607 historical aspects, 599 host range, 603
immune response, 609 immunocompromised individual, 600 interaction with glial cell cultures, 603, 605
laboratory diagnosis, 615
pathogenesis, 600, 607–613 persistence, 608
PML. See Progressive multifocal leukoencephalopathy in pregnancy, 609 prevention, 615 primary infection, 606 proteins, 601–602 reactivation of persistent infection, 608–609 replication, 603, 608 risk factors, 606–607 serodiagnosis, 615
sites of infection, 600 transmission, 606–607
Jaundice, hepatitis, 61, 66–67
JC virus (JCV) animal models, 607–608 attachment and entry into cells, 602–603 biology, 602–606 carcinogenesis, 612–613 cell culture, 603, 605
cell transformation, 605 in cerebellar granule neurons, 614 classification and taxon, 2, 599–600 clinical diagnosis, 612–614 clinical manifestations, 613–615 epidemiology, 604, 606–607 historical aspects, 599 host range, 603
immune response, 609 immunocompromised individual, 600 interaction with glial cell cultures, 603, 605
laboratory diagnosis, 615
pathogenesis, 600, 607–613 persistence, 608
PML. See Progressive multifocal leukoencephalopathy in pregnancy, 609 prevention, 615 primary infection, 606 proteins, 601–602 reactivation of persistent infection, 608–609 replication, 603, 608 risk factors, 606–607 serodiagnosis, 615
sites of infection, 600 transmission, 606–607
Lopinavir/ritonavir (continued)
pharmacokinetics, 194
pharmacology, 193
resistance, 196
structure, 196
Louping ill virus, 1268, 1281
Loveridge’s garter bornaviruses, 1396
Low-density lipoprotein receptor, 1144, 1318–1319
Lujo virus, 141, 1089–1090
animal reservoirs, 1096
clinical manifestations, 1100
epidemiology, 142–144
Lumefantrine, for hemorrhagic fever, 147
Lymphadenitis, HHV-6, 515
Lymphadenopathy
adenovirus, 587
HIV, 811–812
HTLV, 783
Lymphocytes. See B cells; T cells
Lymphocytic choriomeningitis virus (LCMV), 1089–1090
animal reservoirs, 1096
clinical manifestations, 1099
CNS infections, 33–34
differential diagnosis, 1101
epidemiology, 1093–1094
immune response, 328, 338
pathogenesis, 1098–1099
prevention, 1103
serodiagnosis, 307
taxonomy, 3
transmission, 1095, 1098
Lymphocytic interstitial pneumonitis (LIP)
EBV, 534
HIV, 812
Lymphoid cells, innate, 326–327
Lymphoma
EBV, 82–83, 124, 523, 536–537
HHV-6, 515
HHV-8 in, 86
HIV, 813
HTLV-I. See Adult T-cell lymphoma
KSHV, 549, 559–560
Lymphomatoid granulomatosis, EBV, 534
Lymphoproliferative disorder
EBV, 534–535
KSHV, 559–560
Lyssavirus, 967
clinical manifestations, 971–972
differential diagnosis, 972
epidemiology, 970–971
laboratory diagnosis, 972–973
pathogenesis, 968–970
pathology, 970
prevention, 973
treatment, 973–976
virology, 968

M
M032, 434–435
Macaque, B virus, 447, 449, 452–453
Machupo virus, 141, 1089–1090, 1097, 1103
epidemiology, 142, 144
Macrophages, 324–325
HIV-infected, 802–803, 806, 811
Madvira virus (MADV), 1348–1349, 1355, 1360
Madrid virus, 1060
MADV. See Madariaga virus
Major histocompatibility complex (MHC), 327. See also Human leucocyte antigen associations
CD4+ and CD8+ T-cell triggering, 333–334
class I, 334
peptide loading, 335
class II, 334
peptide loading, 335–336
CMV modulation of, 487–488
viral evasion, 336
Mammalian 1 bornavirus, 1396–1397
MAMPs. See Microbe-associated molecular patterns
Mannose receptors, 330
Maraviroc, 134, 170
Marpivir, 134, 170–175, 819
Marburg virus
age-specific attack rates, 989
antigen detection, 996
biology, 985–987
cell culture, 986
classification and taxonomy, 983–984
clinical manifestations, 145–146, 992–996
correlates of disease resolution, 993
diagnosis, 146
distribution and geography, 982–983, 987
duration of infectiousness, 990
epidemiology, 142–144, 982–983, 987, 989–990
genome, 984–985
hemorrhagic fever, 981, 993
histopathology, 992
host range and natural reservoir, 986
immune response, 992–993
inactivation by physical and chemical agents, 986–987
incidence and prevalence of infection, 982, 987
incubation period, 993
isolation, 996
laboratory diagnosis, 996
noseomial infections, 990
nucleic acid detection, 996
ocular manifestations, 162
outbreaks, 981–983, 987, 998
pathogenesis, 144–145, 990–993
PCR methods, 996
pharyngitis, 12
prevention
active immunization, 996–997
management of outbreaks, 998
postexposure prophylaxis, 997–998
proteins, 979–985
replication, 985–986, 990–991
risk factors, 989
serodiagnosis, 996
transmission, 989–990
treatment, 147
antiviral agents, 1000–1001
host-directed therapies, 1001
supportive care, 988–1020
virus composition, 982, 984–985
virology, 983–987
Marburg virus vaccine, 996–998
Maribavir
for CMV infections, 81, 230, 501–503
for EBV, 84, 230
for herpesvirus infections, 230
Masoprostol cream, for warts, 660
Mast cells, 326
Maternal transmission
HIV, 804, 820
HTLV, 776–777, 787
Maturation inhibitors, for HIV, 173, 201
Mayaro virus (MAYV), 1348–1349, 1371–1372, 1374
MCC. See Merkel cell carcinoma
MCD. See Multicentric Castleman’s disease
MCV. See Molluscum contagiosum virus
MDCs. See Myeloid DCs
Meaban virus, 1268
Measles, mumps, and rubella (MMR) vaccine, 130, 353–354, 360, 362, 920, 938–939, 1588–1589
autism and, 921–922
Measles, mumps, rubella, and varicella (MMRV) vaccine, 130, 473, 920, 1388–1389
Measles inclusion body encephalitis, 915–917
Measles virus (MeV)
acute postinfectious measles encephalomyelitis, 916–917
age-specific attack rates, 908–909
antigen detection, 918
antigenic variation, 903–904
atypical measles, 363, 914–915
biology, 906–907
bronchiolitis, 916
cell culture, 294, 904, 907
classification of, 903
clinical diagnosis, 918
clinical manifestations, 300, 910, 913–919
CNS infections, 33–34, 36, 38–40
complications
cardiovascular, 917
gastrointestinal, 917
neurologic, 916–917
ocular, 917
respiratory tract, 916
conjunctivitis, 161, 913–914, 917
croup, 10, 13, 916
cytologic diagnosis, 918
cytopathology, 300
diarrhea, 915–917
distribution and geography, 907–908
duration of infectiousness, 909
encephalitis, 129, 915–917
diagnosis, 915–917
duration and geography, 907–908
epidemic patterns, 908
epidemiology, 907–910
eradicability, 922–923
genetic variation, 903–904
genome, 904
hepatic disorders, 914, 917
historical aspects, 903
HIV-measles virus coinfection, 909, 915, 920–921
host range, 907
immune response, 331, 910, 912–913
immunossay, 289
immunocompromised individual, 915–916, 918
immunosuppression by, 907, 912–913,
921
inactivation by physical and chemical agents, 907
incidence and prevalence of infection, 903–904
incubation period, 910
keratitis, 917
laryngitis, 916
measles inclusion body encephalitis, 915–917

Downloaded from www.asmscience.org by
IP: 54.70.40.11
On: Tue, 23 Jul 2019 13:26:44
modified measles, 914
morbidity and mortality, 907–910
mortality reduction by vaccination, 922
myocarditis, 917
myositis, 914
neonatal infections, 915
nosocomial infections, 909
nucleic acid detection, 918
ocular manifestations, 153, 161
oritis media, 916
pathogenesis, 910–913
pathology, 911–912
PCR methods, 918
pericarditis, 917
pneumonia, 10, 20–23, 129, 915–916
pneumonitis, 914
in pregnancy, 915
prevention
active immunization, 919–923
passive immunophrophylaxis, 919
proteins, 904–906
receptors, 906
reinfection, 909
replication, 905–907, 910–911
risk factors, 909
seasonality, 909
serodiagnosis, 307–308, 312, 918–919
serotypes, 903
sinusitis, 916
skin lesions, 115–116, 911, 913–914, 918
diagnosis, 129–130
epidemiology and clinical manifestations, 129
treatment, 130
subacute sclerosing panencephalitis, 916–917
subclinical infection, 908–909
taxonomy, 3, 903
thrombocytopenia/thrombocytopenic purpura, 918
tracheobronchitis, 10, 914, 916
transmission, 909
treatment
antiviral drugs, 923–924
symptomatic and supportive therapy, 923
vitamin A, 923
tuberculosis and, 918
typical measles, 913–914
viremia composition, 904–906
viremia structure, 904
virology, 903–906
administration, 920–921
adverse effects, 921–922
contraindications, 922
investigational, 922
supplementary immunization activities, 923
vaccination strategies, 922–923
Meat and bone meal, 1438
MEDI852, 285
MEDI8907, 285
Meltofloxine, for PML, 615
MELA. See Micro-enzyme immunoassay
Melnoma, HSV gene therapy for, 434
Membrane cofactor protein, 906
Membrane-immunoassay, 298
Memory, immune, 354–355
B cells, 340–341
NK cell, 327
Menangle virus
Menangievirus
Meningitis
Approach to patient, 42–43
aseptic, 31–32, 37
clinical manifestations, 36
definition, 31
diagnosis, 32–34, 37, 42
treatment, 37–38
transmission, 37–38
VZV, 468–469
Meningoencephalitis
adenovirus, 857
coxsackievirus, 1123–1124
HSV, 427
MenPV. See Menangle virus
Mercatine, 247
Merkel cell carcinoma (MCC), 607, 612, 614, 616
Merkel cell polyomavirus
attachment and entry into cells, 602–603
biology, 602–606
cell transformation, 605
classification and taxonomy, 599–600
epidemiology, 606–607
historical aspects, 599
immunocompromised individual, 600
pathogenesis, 600, 612
peristence, 608
proteins, 601–603
replication, 603, 608
risk factors, 607
sites of infection, 600
transmission, 606–607
treatment, 616
viremia structure and composition, 599–601
Merck cell virus, 612–614
Merlin genome, CMV, 482–485
MERS-CoV. See Middle East respiratory syndrome coronavirus
Metapneumovirus (MPV)
active immunization, 888
age-specific infection rates, 875–877
animal viruses, 874–875
antigen detection, 885–886
antiviral drugs, 889–890
asthma and, 883, 884–885
bronniolitis, 10, 16, 883
cell culture, 292, 885–886
classification and taxonomy, 3, 873–874
clinical attack rate, 876–877
clinical diagnosis, 885
clinical manifestations, 882–883
common cold, 10
complications, 884–885
correlates of immune protection, 881
croup, 883
cytopathic effect, 885–886
distribution and geography, 875
epidemics, 877–878
epidemiology, 875–878
genome, 873–875
histopathology, 878–879
historical aspects, 873
host range, 874–875
immune response, 879–881
immunoassay, 298
immunocompromised individual, 876, 878–879, 884
isolation, 885–886
laboratory diagnosis, 885–886
myocarditis, 100
nosocomial infections, 878, 886–887
nucleic acid detection, 886
organ specificity, 878
oritis media, 883–884
pathogenesis, 878–879
PCR methods, 886
pneumonia, 10, 19, 883
prevention, 886–888
protein, 873–875
reinfection, 876–877
replication, 874, 876, 878
respiratory disease, 873, 875–890
sample collection and handling, 885
seasonality, 877–878
serodiagnosis, 886
stability, 875
transmission, 878
treatment
severe disease, 889
supportive care, 888–889
viremia structure, 873–875
virology, 873–876
virus replication patterns, 878
Metapneumovirus (MPV) vaccine, 888
Methylprednisolone, for hantavirus cardiopulmonary syndrome, 1073
Metisazoan, for poxvirus infections, 407
Metoclopramide, for filovirus infection, 998
Metoprolol, for myocarditis-related heart failure, 107
Me Tri virus, 1348, 1374
MeV. See Measles virus
MF59, 358
MHAA549A, 285
MHC. See Major histocompatibility complex
MHV. See Murine hepatitis virus
Microbe-associated molecular patterns (MAMPs), 328–329
Micro-enzyme immunoassay (MELA), 298–299
Microgal cells, HIV-infected, 811
Microvasculopathy, HIV, 154
Mizadolam, for rabies, 974–976
Middleburg virus (MIDV), 1347, 1349, 1353
Middle East respiratory syndrome coronavirus (MERS-CoV) animal reservoir, 1245 biology, 1245–1248 cell culture, 1247 classification and taxonomy, 1243–1244 clinical manifestations, 1255 diagnosis, 304–305 distribution and geography, 1248 experimental animal models, 1247 gastroenteritis, 53 genome, 1245–1246 historical aspects, 1243 host range, 1247 immune response, 1253 inactivation by physical and chemical agents, 1248 incidence and prevalence of infection, 1249 laboratory diagnosis, 1255–1256 nosocomial infections, 1251 pathogenesis, 1252–1253 pneumonia, 20 prevention, 1256–1257 replication, 1252 risk factors, 1252 serodiagnosis, 1256 transmission, 1251 treatment, 1257

Middle East respiratory syndrome coronavirus (MERS-CoV) vaccine, 1257

MIDV. See Middelburg virus

Military personnel
adenovirus, 586
hepatitis, 61, 1165
Milker's nodules, 116, 120–121, 138, 402–403. See also Pseudocowpox virus

Milirminon, for myocarditis-related heart failure, 107

Milwaukee protocol, for rabies, 974–976

Minichromosome, HBV, 719–720

Minireovirus, 48

Miravirsen, 247

miRNAs
EBV, 526–528
KSHV, 561–562

Mirtazapine, for PML, 615

Mites, alphavirus, 1353

Mixed cell culture, 294

Mixed cryoglobulinemia

Mixed cuglobulinemia HBV, 730

HCV, 131, 1327

Mixing vessel, 1018

MK-3682, 247, 1333

MK-8408, 247, 1333

MK-8591, 172

MMR vaccine. See Measles, mumps, and rubella vaccine

MMRV vaccine. See Measles, mumps, rubella, and varicella vaccine

Modified Ankara virus (MVA) vaccine, 406–407

Moloc virus, 1269, 1273, 1281

Mojave virus (MojPV), 949, 956

MojPV. See Mojave virus

Mokola virus, 968, 976

Molecular biology, 1

Mollaret's syndrome, 36


Monkeys
bornavirus, 1402 B virus, 447, 449, 452–453 chikungunya virus, 1367 HEV, 1221 immunodeficiency viruses, 795 Mayaro virus, 1371

Monochloroacetic acid, for warts, 657

Monocytes

Monocytes, alphavirus, 1353

Monophosphoryl lipid A, 358

Monospot test, 125, 309

Monophosphoryl lipid A, 358

Monospongyosis, EBV, 84

Monophosphoryl lipid A, 358

Monosporin test, 125, 309

Montana myositis leukoencephalitis virus, 1269

Montgomery County agent, 48

Morbillivirus, 903

Mosquito

Mosso das Pedras virus, 1348

Mouse pneumotropic virus, 599, 606–609

Mouse polyomavirus, 606–607

Mousepox virus, 400

MPV. See Metapneumovirus

MPXV. See Monkeypox virus

Mucambo virus, 1348, 1357

Mucocutaneous infection, HSV, 423–425, 435–436

Mucosal barriers, 323–324

Mucosal immunity
immunologic basis of vaccination, 358 metapneumovirus, 882–881 parainfluenza virus, 880–881 RSV, 880–881

Mucus
barrier immunity, 324

Multiple sclerosis, HHV-6, 515

Multiplex PCR, 301–302

Mumps virus


Murina bornavirus 1, 1396

Murine hepatitis virus, 612

Murray Valley encephalitis virus, 33–34, 1268, 1272, 1274, 1279–1280

SUBJECT INDEX
N

NAC. See N-acetyl-L-cysteine

N-acetyl-L-cysteine (NAC), for KSHV, 565

Nairobi sheep disease virus, 1060

Nairovirus
cell culture, 1061–1063
classification and taxonomy, 1059–1060
clinical manifestations, 1078–1079
distribution and geography, 1060
epidemiology, 1062–1063, 1077–1078
genome, 1059–1060
host range, 1061–1063
laboratory diagnosis, 1079
pathogenesis, 1077
prevention, 1079–1080
protein, 1059–1060
replication, 1060–1061
subgroups, 1060
transmission, 1063
treatment, 1080

viron structure, 1059–1060
virology, 1059–1062
NALPs, 331
Naproxen, for common cold, 12
Narangil virus, 1268
Nasreen, 1275
Nasopharyngeal carcinoma, EBV, 124, 489, 493
Nef protein, HIV, 799–800, 802
Negishi virus, 1281
Neutralization assay, 309–310
Neutropenia, HIV, 813
Neutrophils, 325–326
Nevirapine
adverse effects, 177, 185
clinical applications, 170, 186
cutaneous adverse effects, 134
dosing regimen, 170
drug interactions, 177, 185
for HIV, 170, 177, 184–186
perinatal administration, 820
pharmacokinetics, 177
pharmacology, 185
resistance, 185–186
structure, 185
New Jersey polyomavirus, 600, 614–615
New Mapoon virus, 1268
New York virus, 1065, 1068
NPC. See Nonspecific follicular conjunctivitis
NHR. See Necrotizing herpetic retinopathies
Nipah virus (NiV)
animal reservoirs, 950, 954–955
antigen detection, 959
biology, 953
classification and taxonomy, 3, 949
clinical diagnosis, 958
clinical manifestations, 300, 950, 958
complications, 958
cytopathology, 300
distribution and geography, 954
eenchalitis, 950, 954, 957–958
epidemiology, 954
genome, 949–951
histopathology, 957
immune response, 957
isolation, 959
laboratory diagnosis, 958, 959
neurologic disorders, 958
pathogenesis, 957
pneumonia, 950, 958
prevention, 959–960
proteins, 951–953
receptors, 953
serodiagnosis, 959
transmission, 954
treatment, 960
vasculitis, 957–958, 960
virology, 949–953
Orchitis, mumps virus, 933, 935, 937, 939
Orf virus (ORFV)
barnyard infections, 397
classification and taxonomy, 2, 387–388
clinical diagnosis, 405
clinical manifestations, 388, 402–403
epidemiology, 388, 395, 397
host range, 388
laboratory diagnosis, 405
pathogenesis, 400
skin lesions, 116, 120–121
structure, 389
Organ transplant recipient. See Transplant recipient
Oriboca virus, 1060
Orpharyngeal cancer, HPV, 640
Orpharyngeal infection, HSV, 420–421, 426–427
treatment, 435, 437
Orpharyngeal infections, HSV, 424
Orpouche virus, 1060
Orthomyxovirus, classification and taxonomy, 3
Oropharyngeal cancer, HPV, 640
Oropouche virus, 1060
Oseltamivir
adverse effects, 276, 280, 1042
clinical applications, 274, 280–281
dosing regimen, 274
drug interactions, 276, 280
effectiveness of, 1039
for influenza, 272, 274, 276–277, 279–281, 1039, 1041–1042
mechanism of action, 279
pharmacokinetics, 276, 279–280
for pneumonia, 22–23
resistance, 280, 1041–1042
spectrum of activity, 279
structure, 272, 277, 279
susceptibility testing, 295–296
Otitis media
adenovirus, 588
coronavirus, 1254
influenza virus, 1027–1029
measles virus, 916
metapneumovirus, 883–884
parainfluenza virus, 884
rhinovirus, 1154
RSV, 882, 884
secondary bacterial, 1154
Oxymetazoline, for common cold, 1157

P
Palivizumab, 364
for bronchiolitis, 17
for pneumonia, 23
for RSV infections, 282, 351, 887
PAMPs. See Pathogen-associated molecular patterns
PAN. See Polyarteritis nodosa
Pancreatitis, mumps-associated, 937
Parvovirus
antigen, 681, 685
Papillomavirus. See also specific papillomaviruses
animal, 635
ocular manifestations, 153, 162
phylogenetic tree, 626
skin lesions, 115–116
taxonomy, 2
Pap smear, 299, 643, 650, 655–656
Parainfluenza virus (PIV)
active immunization, 887–888
age-specific infection rates, 875–877
animal viruses, 874–875
antigen detection, 885–886
antiviral drugs, 889–890
bronchiolitis, 10, 16, 883
cell culture, 292–294, 885–886
classification and taxonomy, 3, 873–874
clinical attack rate, 876–877
clinical diagnosis, 885
clinical manifestations, 300, 882–883
CNS infections, 36
common cold, 10
complications, 884–885
correlates of immune protection, 881
croup, 10, 13, 873, 878, 883, 888–889
cytopathic effect, 885–886
cytopathology, 300
distribution and geography, 875
epidemics, 877–878
epidemiology, 875–878
genome, 873–875
histopathology, 878–879
historical aspects, 873
host range, 874–875
immune response, 331, 879–881
immunossay, 297–298
immunocompromised individual, 876, 878, 884, 889
isolation, 885–886
laboratory diagnosis, 885–886
nosocomial infections, 878, 886–887
nucleic acid detection, 886
organ specificity, 878
otitis media, 884
pathogenesis, 878–879
PCR methods, 886
pharyngitis, 10
pneumonia, 10, 19–23, 879, 883, 884
prevention, 886–888
proteins, 873–875
reinfection, 876–877
replication, 874, 876, 878
respiratory disease, 873, 875–890
sample collection and handling, 885
seasonality, 9, 11, 877–878
serodiagnosis, 886
stability, 875
tracheobronchitis, 10
transmission, 878
transplant recipient, 884
treatment
severe disease, 889
supportive care, 888–889
virology, 873–875
virology, 873–876
virus replication patterns, 878
Parainfluenza virus (PIV) vaccine, 359, 887–888
Paralysis
coxsackievirus, 1125
poliovirus, 1113, 1119, 1123, 1125
Paralytic rashes, 971–972
Paramyxovirus
taxonomy, 3
zoonotic, 949–953, 956
Parechovirus, ocular manifestations, 160–161
Parental transmission. See Bloodborne transmission; Transplant recipient
Paritaprevir, 245, 251, 254–255, 1332–1334
Parotitis
influenza virus, 1030
mumps virus, 929, 933–939
Paramyotus agent, 48
Parrot bornaviruses, 1396
PARV4. See Tetraparvovirus
Parvovirus
antigen detection, 689
cell culture, 682
chronic fatigue syndrome, 372
classification and taxonomy, 2, 679–680
clinical manifestations, 686–688
distribution and geography, 682
epidemiology, 682–683
genoType, 680–681
genotypes, 679–680
historical aspects, 679
host range, 679, 681–682
immune response, 686
inactivation by physical and chemical agents, 682
incidence and prevalence of infection, 683–684
isolation, 689
laboratory diagnosis, 688–689
pathogenesis, 683–686
PCR methods, 689
prevention, 690
proteins, 680–681
receptors, 681
replication, 681, 684–686
seasonality, 684
serodiagnosis, 689
transmission, 683
treatment, 690
virology, 679–681
virology, 679–682
Parvovirus B19 (B19V)
antigen detection, 689
arthralgia, 687, 690
arthritis, 684, 687, 690
asymptomatic infection, 686
cell culture, 682
classification and taxonomy, 2, 679–680
clinical manifestations, 300, 686–688
cytology, 300
distribution and geography, 682
drastic disease, 688
epidemiology, 682–683
erythema infectiosum. See Erythema infectiosum
genome, 679–680
phylogenetic tree, 626
primary care, 888–889
virology, 873–875
virology, 873–876
viruses, 872–878
viruses, 873–875
virus replication patterns, 878
Parainfluenza virus (PIV) vaccine, 359, 887–888
Paralysis
coxsackievirus, 1125
poliovirus, 1113, 1119, 1123, 1125
Paralytic rashes, 971–972
historical aspects, 1113
immune response, 331, 1122
isolation, 1130
laboratory diagnosis, 1130–1131
myocarditis, 99
neurologic disease, 1122–1123
analysis, 1113, 1119, 1123, 1125
pathogenesis, 1120–1122
prevention, 1131–1132
protection polyomavirus, 1121
replication, 1116–1118
treatment, 1132–1133
tropism, 1120–1121
vaccine-derived, 1114, 1119, 1131
virion structure, 1114–1115
virology, 1113–1118
Poliovirus vaccine, 1, 41, 351–352, 354, 358, 359–360, 1114, 1119, 1131
Pol proteins
HIV, 798–799, 802
HTLV, 772–773
Poxvirus nodosa (PAN), 66, 731
Polymerase chain reaction (PCR) assay, 301
amplicon detection, 301
CNS infection diagnosis, 37, 41
cells, 305
treatment, 301–302
novel and emerging infection diagnosis, 305–306
quantitative, 304–305
real-time, 302–303, 305
routine infection diagnosis, 305
Polyomaviridae, HTLV, 783, 785
Polyomavirus
animal models, 607–608
attachment and entry into cells, 602–603
biology, 602–606
carcinogenesis, 612–613
cell culture, 603, 605
cell transformation, 605
classification and taxonomy, 2, 599–600
clinical manifestations, 300, 613–615
cytology, 299–300
epidemiology, 604, 606–607
genome, 599–601
historical aspects, 599
host range, 603
immune response, 609
immunocompromised individual, 600,
604, 606–616
inactivation by chemical and physical agents, 606
interaction with glial cell cultures, 603, 605
laboratory diagnosis, 615
Merkel cell carcinoma, 607, 612, 614, 616
pathogenesis, 605, 607–613
persistence, 608
PML. See Progressive multifocal leukoencephalopathy in pregnancy, 609
prevention, 615
primary infection, 606
proteins, 601–604
reactivation of persistent infection, 608–609
renal and urological disease, 607, 610–612
replication, 603, 608
risk factors, 606–607
serodiagnosis, 615
sites of infection, 600
skin lesions, 323
transmission, 606–607
transplant recipient, 75–76, 87–88,
606–607
treatment, 615–616
urinary excretion, 609
virion structure and composition, 599–601
virology, 599–606
Polyriboadipathy, CMV, 492, 495
Polythiophenes, prion disease, 1439
Porcine respiratory coronavirus, 1247
Porcine rotavirus, 842
PORN. See Progressive outer retinal
necrosis
Porphyria cutanea tarda (PCT), HCV, 131
Postexposure prophylaxis
arenavirus, 1163
herpesviruses, 997–998
hepatitis viruses, 69
HIV, 819
immunoglobulin preparations, 364
rabies virus, 42, 967, 973–975
Postexposure vaccination, 352
Postherpetic neuralgia, 123–124, 158–159,
420, 470, 473
Postinfection prophylaxis vaccination, 352
Postinfectious encephalitis. See Acute
disseminated encephalomyelitis
Postinfective fatigue syndrome
clinical assessment, 376–378
diagnostic criteria, 373
epidemiology, 373
etiology, 373
geneic predisposition, 376–378
immunologic disturbance, 374–377
infectious, 372, 374, 377
metabolic or neuroendocrine disturbance,
375–377
psychological disturbance, 372, 375, 377
HHV-6, 372, 374, 378
historical perspective, 371–372
laboratory assessment, 376–378
natural history, 373
treatment, 378–379
Postnatal infection, CMV, 489, 493–494
Posttransplant lymphoproliferative disease
(PostPTLD)
EBV, 75, 83–85, 535–536
HHV-8 in, 86–87
treatment, 84–85
Powassan virus, 1268, 1272, 1280
Poxvirus. See also specific poxviruses
age-related differences, 403
age-specific attack rates, 407
antigen detection, 405
antiviral resistance, 408
barnyard infections, 397
biology, 388–389, 394–395
cell culture, 395, 405
classification and taxonomy, 2, 387–388
clinical diagnosis, 405
clinical manifestations, 388, 401–405
complications, 403–405
distribution and geography, 395
duration of infectiousness, 398
epidemiology, 388, 395–398
genome, 388, 390–393
histology, 405
histopathological changes, 399–400
historical aspects, 387
host range, 388, 394–395
immune response, 326, 400–401
inactivation by physical and chemical
agents, 395
incidence and prevalence, 395–397
incubation period, 398
laboratory diagnosis, 405
nosocomial infections, 398
ocular manifestations, 153, 161
pathogenesis, 398–401
patterns of infection, 395–396
PCR methods, 405
prevention
active immunization, 406–407
outbreak management, 407
passive immunophrophylaxis, 406
carantine, 406
proteins, 388–394
reinfections, 397
replication, 388–390, 394, 398–399
risk factors and high-risk groups, 397
seasonality, 397
serodiagnosis, 405
skin lesions, 115–116, 119–121, 321
specimens, 405
spread of virus, 398–399
structure, 388–393
subclinical infection rate, 395
transmission, 397–398
treatment
antiviral agents, 407–408
supportive and local care, 407
virology, 387–395
PPI-668. See Ravidasvir
PRA. See Plaque reduction assay
Prednisolone, for parainfluenza virus
infections, 889
Prednisone
for adult T-cell lymphoma, 786
for myocarditis, 107
Preexposure prophylaxis (PrEP)
HIV, 818–819
immunoglobulin preparations, 364
rabies virus, 42, 973
Pregabalin, for herpes zoster, 124
Pregnancy
arenavirus in, 1100
BK virus, 609
CMV in, 125, 488–489, 493–494
Colorado tick fever virus, 846
EBV, 532
filovirus in, 995
HAV, 1178
HIV, 737
HCV, 1322, 1329
hepatitis in, 62, 64–65, 69–70
HEV, 1209, 1216–1217, 1221–1222
HIV, 804, 820
HPV, 655
HSV, 422, 428
HTLV, 786
influenza virus, 1028–1029
Japanese encephalitis virus, 1278
JC virus, 609
measles virus, 915
mumps virus, 936–937
parvovirus B19, 687, 690
polyomavirus, 609
RSV, 888
rubella virus, 1381, 1383–1384,
1388–1389
vaccination, 362
Protein pp71, CMV, 482

Prochlorperazine, for dengue virus, 1298


gene, 1426

HCV, 1331

viral persistence, 608

pathogenesis, 609

laboratory diagnosis, 615

immune response, 610

animal models, 607

Protein pp71, CMV, 482

Proventricular dilatation disease (PDD)

bornavirus, 1396–1399

comparative analysis, 1401–1402

PRRs. See Pattern recognition receptors

Pseudocowpox virus (PCPV)

barnyard infections, 397

classification and taxonomy, 387–388

clinical diagnosis, 405

clinical manifestations, 388, 402–403

epidemiology, 388, 395, 397

host range, 388

laboratory diagnosis, 405

structure, 389

Pseudoeuherine, for common cold, 12

Psittaciform 1 bornavirus, 1396

Psittacifacm 2 bornavirus, 1396

Psychiatric disease, bornaviruses, 1401

Psychological disorder, chronic fatigue syndrome, 372, 375, 377

PTLD. See Posttransplant lymphoproliferative disease

Punta Toro virus, 1060

Pure red-cell aplasia, parvovirus B19, 687

Pumula virus, 142, 1066–1068, 1071

PV. See Poliovirus

pX II protein, HTLV, 772–774, 778–779

pX I protein, HTLV, 772–774, 778–779

Pyrogenic cytokines, 332

Q

QS21, 358

Quality assurance and control, diagnostic virology, 313–314

QuantiFERON-CMV assay, 77–78

Quantitative PCR, 304–305

Quarantine, smallpox, 406

R

RahAvert, 354, 973

Rabbitpox virus, 395

Rabies, 972

Rabies hyperimmunoglobulin, 364, 973

Rabies virus

animal reservoirs, 967

classification and taxonomy, 3, 967–968

clinical manifestations, 971–972

CNS infections, 33–34, 38–42

differential diagnosis, 972

encephalitis, 967, 970, 971–972

epidemiology, 970–971

historical aspects, 967–968

hydrophobia and aerocephalitis, 972

immunossay, 298

incubation period, 971

laboratory diagnosis, 972–973

paralytic, 971–972

pathogenesis, 968–970

pathology, 970

postexposure prophylaxis, 967, 973–975

preexposure prophylaxis, 973

prevention, 973

serodiagnosis, 307, 310

transplant recipient, 968–969

treatment, 967, 973–976

virology, 968

Rabies virus vaccine, 41–42, 352, 354, 967, 973–975

Raccoons, rabies virus, 970–971

Racecadotril, for rotavirus infections, 866

Radiculitis, 31

Radiculomyelitis, HSV, 427, 431

Radioimmunoassay (RIA), 298

serodiagnosis, 311

Ralegravir

adverse effects, 189, 190

clinical applications, 170, 191

cutaneous adverse effects, 134

dosing regimen, 170

drug interactions, 189, 190

for HIV infections, 170, 189–191

for HTLV-associated myelopathy, 787

pharmacokinetics, 190

pharmacology, 189

resistance, 189, 191

structure, 189

Ramipril, for myocarditis-related heart failure, 107

Ramsay Hunt syndrome, 123, 470

Rapamycin, for KSHV, 565

Ravidasvir (PPI-668), 261

Real-time PCR, 302–303, 305

CMV detection, 496

Recombinant polymerase amplification, 303–304

Recombivax HB, 353, 359, 361

REGN222, 285

Regulatory T cells (Tregs), 339–340

Rehydration therapy

for arenavirus infection, 1104

for filovirus infection, 999–1000

for rotavirus-induced diarrhea, 865–866

Renal disease

BK virus, 87–88, 607

clinical manifestations, 614

immune response, 611

laboratory diagnosis, 615

pathogenesis, 610–612

prevention and treatment, 615–616

virological features, 611–612

filovirus, 995

Reovirus

arthropod-borne

biology, 843–844

classification and taxonomy, 841–842

clinical manifestations, 846–847

differential diagnosis, 846–847

distribution and geography, 843–844

ecology, 843–845

epidemiology, 843–845

genoeh, 841, 843–844

historical aspects, 841

immune response, 845–846

laboratory diagnosis, 846–847

organ and cellular pathology, 845

pathogenesis, 845–846

prevention, 847

proteins, 843–844

treatment, 847–849

virology, 841–843

taxonomy, 3

Reptiles

alphavirus, 1353

bornavirus, 1396, 1398

RespiGam, 364

Respiratory disease

adenovirus, 753, 580–582, 584–588, 590

antiviral agents for influenza virus, 271–282

investigational, 283–285

RSV, 273–276, 282, 285

bronchiolitis. See Bronchitis
cell culture, 294
common cold. See Common cold
coronavirus, 1243, 1248–1250,
1252–1257. See also Severe acute respiratory syndrome coronavirus
croup. See Croup
titerovirus, 1126–1127
titerovirus, 10
titerovirus, 994–995
human bocavirus, 688
metapneumovirus, 873, 875–890
mortality, 9
parainfluenza virus, 873, 875–890
pharyngitis. See Pharyngitis
pneumonia. See Pneumonia
rotavirus, 863
RSV, 873, 875–890
seasonal patterns, 9, 11
tracheobronchitis. See Tracheobronchitis
Respiratory papillomatosis, recurrent clinical manifestations, 648
epidemiology, 638
HPV, 625, 627, 638–641, 648, 653,
658–659, 663
prevention, 653
risk factors, 639, 641
transmission, 640–641
treatment, 658–659, 663
Respiratory syncytial virus (RSV) active immunization, 887–888
age-specific infection rates, 875–877
animal viruses, 874–875
antigen detection, 885–886
antiviral drugs, 889–890
asthma and, 884–885
bronchiolitis, 10, 15–18, 873, 876–879,
881–882, 884
cell culture, 292–294, 885–886
classification and taxonomy, 3, 873–874
clinical attack rate, 876–877
clinical diagnosis, 885
clinical manifestations, 300, 881–883
common cold, 10
complications, 884–885
correlates of immune protection, 881
croup, 10, 13
cytopathic effect, 885–886
cytopathy, 332
distribution and geography, 875
in elderly, 882–883
epidemics, 877–878
epidemiology, 875–878
genome, 873–875
histopathology, 878–879
historical aspects, 873
host range, 874–875
immune response, 326, 331, 332,
879–881
immunossay, 297–298
immunocompromised individual, 876,
878, 894, 889
investigational antiviral drugs for,
283–285
isolation, 885–886
laboratory diagnosis, 885–886
maternal immunization, 888
mortality, 9
myocarditis, 100, 106
nosocomial infections, 878, 886–887
nucleic acid detection, 886
organ specificity, 878
oritis media, 882, 884
palivizumab for, 282, 351, 887
passive immunophylaxis, 887
pathogenesis, 878–879
PCR methods, 886
pharyngitis, 10
pneumonia, 10, 19–23, 873, 876–877,
879, 881–882, 884
in pregnancy, 888
prevention, 886–888
proteins, 873–875
 reinfection, 876–877
replication, 874, 876, 878
respiratory disease, 873, 875–890
ribavirin for, 273–276, 282, 285
sample collection and handling, 885
seasonality, 9, 11, 877–878
serodiagnosis, 886
stability, 875
transmission, 878
transplant recipient, 884
treatment
severe disease, 889
supportive care, 888–889
virus structure, 873–875
virology, 873–876
virus replication patterns, 878
Respiratory syncytial virus (RSV) immune globulin, 364, 889
Respiratory syncytial virus (RSV) vaccine, 879, 881–888
Respiratory viruses, in transplant recipient, 75
Reston virus, 981, 984, 989
Retinovirus
BK virus, 614
CMV, 153–155, 157–158, 163,
223–227, 492, 494, 503
common viral pathogens, 153–154
VZV, 470
Retinoic acid, for HPV infections, 119
Reye syndrome, 1027
Serotype, 151–154
Rhinovirus (RV) acid lability, 1143
antigen detection, 1156
antiviral drugs, 1157–1158
asthma and, 1154–1155
biology, 1146–1150
bronchiolitis, 10, 16, 1155
buoyant density in cesium chloride, 1143
cell culture, 292–293, 1149–1150, 1156
classification, 1143
clinical diagnosis, 1155
clinical manifestations, 1154–1155
common cold, 10–11
complications, 1154–1155
croup, 10, 13
cytopathic effect, 1149
distribution and geography, 1150
duration of infectiousness, 1151
tenterovirus reclassification, 1113–1114
epidemiology, 1150–1151
exacerbation of chronic bronchitis, 1154–1155
factors in disease expression, 1152–1153
genome, 1143, 1146
historical aspects, 1143
host range, 1149
immune response, 1153
immunocompromised individual, 1155
inactivation by physical and chemical agents, 1150
incidence and prevalence of infection, 1150
incubation period, 1151–1152
isolation, 1156
laboratory abnormalities, 1154
laboratory diagnosis, 1156
mouse model of, 1149
neutralization by immunoglobulins, 1145,
1153
nucleic acid detection, 1156
oritis media, 1154
otologic changes, 1154
pathogenesis, 1151–1154
PCR methods, 1156
pharyngitis, 10
phylogenetic groups, 1144
pneumonia, 10, 19–21, 1155
prevention, 1156–1157
proteins, 1146–1147
receptors, 1144
replication, 1146–1149
patterns of, 1152
RV-C viruses, 1144
seasonality, 9, 11, 1150–1151
serodiagnosis, 1156
serotypes, 1143–1144
sinusitis, 1154
taxonomy, 4
tracheobronchitis, 10
transmission, 1151
treatment, 1157–1158
virology, 1144–1145
virus composition, 1144–1145
virology, 1143–1146
RIA, See Radioimmunoassay
Ribavirin
for adenovirus infections, 590
adverse effects, 249, 276, 1331
for arenavirus, 1103, 1104–1105
virology, 968
in pregnancy, 888
pharyngitis, 10
pneumonia, 10, 19–23, 873, 876–877,
879, 881–882, 884
treatment, 973–976
treatment, 973–976
virology, 968
Rilpivirine for hepatitis C, 63, 70, 131
for HIV, 170, 189
for HPV infections, 249, 276, 363, 365, 366
for severe fever with thrombocytopenia syndrome, 1077
for Sandfly fever virus, 1076
for Rift Valley fever, 1078
for parainfluenza virus infections, 890
Ribonucleoproteins (RNPs), bornavirus, 1396
Ribovirine, HDV, 1409–1410
Rift Valley fever (RVF) virus, 141, 1059, 1060, 1063
cell culture, 294, 1382
clinical manifestations, 146, 1074–1075
diagnosis, 1075
epidemiology, 142–144, 1074
ocular manifestations, 162
pathogenesis, 144–145, 1074
prevention, 1075
taxonomy, 3
treatment, 1075
Rift Valley fever (RVF) virus vaccine, 148, 1075
RIG-I-like receptors, 331
Rilpivirine adverse effects, 188
clinical applications, 170, 188–189
dosing regimen, 170
drug interactions, 188
fixed-dose combination, 197
for HIV, 170, 185, 188–189
pharmacology, 188
resistance, 188
structure, 185
Rimantadine adverse effects, 276–277
clinical applications, 273, 277
dosing regimen, 273
drug interactions, 276
effectiveness of, 1039
for influenza, 272–273, 276–277, 1009, 1039, 1041
mechanism of action, 277
pharmacokinetics, 276–277
resistance, 277, 1041
spectrum of activity, 277
structure, 272, 277
susceptibility testing, 295
Rinderpest virus, 903
Rintatolimod, for chronic fatigue syndrome, 378
Rio Bravo virus, 1269, 1281
Rio Mamore virus, 1065
Rio Negro virus, 1348
Rio Segundo virus, 1065
Ritonavir, 245.
for EBV-associated disease, 85, 125, 535–536
for KSHV, 126, 565
PML, 604, 607
R-Mix, 294
RNA reverse transcribing viruses, taxonomy, 2–3
RNA viruses, taxonomy, 3–4
RNPs. See Ribonucleoproteins
Rocio virus, 1269, 1272
Rodents cell culture, 857
celiac disease and, 864
biliary atresia and, 864
celiac disease and, 864
cell culture, 857–858, 864
classification and taxonomy, 3, 853–854
clinical manifestations, 863–864
complications, 863–864
correlates of disease resolution, 863
correlates of immune protection, 862–863
diabetes and, 864
diagnosis, 306
distribution and geography, 858–860
electron microscopy, 80
epidemic patterns, 859
epidemiology, 858–860
gastroenteritis, 47–55, 853, 860–866
genome, 854–856
global distribution of deaths, 853–854
groups A through E, 853
histopathology, 860–861
historical aspects, 853
host range, 857
immune response, 861–863
immunoassay, 298
immunocompromised individual, 859–860
incidence and prevalence of infection, 858–859
incubation period, 860
intussusception, 863–865
isolation, 864
laboratory diagnosis, 864
neonatal infections, 859
nosocomial infections, 860
nucleic acid detection, 864
pathogenesis, 860–863
PCR methods, 864
prevention
active immunization, 865
passive immunoprophylaxis, 864–865
proteins, 855–857
reinfections, 860
replication, 857–858, 860
respiratory disease, 863
risk factors and high-risk groups, 859–860
seasonality, 859
seizures, 864
serodiagnosis, 864
serotypes, 853–854
subclinical infections, 859
transmission, 860
treatment, 865–866
virology, 853–858
virion composition, 854–857
virion morphology, 854–855
virology, 853–858
Rotavirus vaccine, 50–51, 55, 354, 359–360, 363, 365, 862–865
Royal Farm virus, 1268
RRV. See Ross River virus
RSER virus. See Russian spring-summer encephalitis virus
RSV. See Respiratory syncytial virus
RT-PCR. See Reverse transcription-PCR
Rubella virus arthralgia, 1386–1387
arthritus, 1386–1387, 1389–1390
biology, 1382
cardiovascular disease, 1387
cell culture, 294, 1382
classification, 1381–1382
clinical manifestations
congenital rubella, 1387–1388
postnatal rubella, 1386–1387
complications, 1386–1387
congenital infection, 163
diabetes and, 1388
differential diagnosis, 1387
distribution and geography, 1382
eencephalitis, 1387, 1390
epidemiology, 1382–1384
Fuchs heterochromic iridocyclitis, 1386
genome, 1382
hearing loss, 1387
histopathology
congenital rubella, 1385
postnatal rubella, 1384–1385
historical aspects, 1381
immune response
congenital rubella, 1385–1386
postnatal rubella, 1385
immunoperoxidase, 298
inactivation by physical and chemical agents, 1382
incidence and prevalence of infection, 1382–1383
laboratory diagnosis, 1388
myocarditis, 100
neurologic disease, 1387–1388
ocular complications, 1388
ocular manifestations, 153, 157, 163
pathogenesis, 1384–1386
in pregnancy, 1381, 1383–1384, 1388–1389
prevention
active immunization, 1388–1389
passive immunoprophylaxis, 1388
proteins, 1382
replication, 1384
seasonality, 1383
serodiagnosis, 307–308, 312, 1388
skin lesions, 115–116, 130, 1386–1387
subclinical illness, 1386
taxonomy, 4, 1381–1382
thrombocytopenic purpura, 1387, 1389
transmission, 1384
treatment, 1389–1390
virion composition, 1382
virology, 1381–1382
rubella virus vaccine, 41, 351–352, 354, 1381, 1383–1384, 1388–1389
adverse effects, 1389
contra indications, 1389
Rubeola. See Measles virus
Russian spring-summer encephalitis (RSSE)1284–1287
RV. See Rhinovirus
RV1. See Rotarix
RV5. See RotarTec
RVF virus. See Rift Valley fever virus
RVFV assay, 302

S
Saaramea virus, 1066, 1071
Sabin virus, 142, 1089–1090, 1095, 1097
Saboya virus, 1269
Saddleback fever, 846
Sagiyama virus, 1349
St. Croix River virus, 842
St. Louis encephalitis virus, 1268
animal models, 1280
arthropod vectors, 1272
biology, 1280
cell culture, 1272
chronic fatigue syndrome, 372
clinical manifestations, 1283
CNS infections, 33–34, 38, 40
diagnosis, 1283–1284
differential diagnosis, 1362
distribution and geography, 1280, 1282
epidemiology, 1280, 1282–1283
host range, 1272
incidence and prevalence of infection, 1280, 1282
pathogenesis, 1274, 1283
prevention, 1284
risk factors, 1283
transmission, 1283
treatment, 1284
Salicylic acid
for HPV infections, 119
for warts, 657
Saliva
CMV detection, 495
testing for viral antibodies, 309
Salivary gland carcinoma
HHV-6, 515
Salmon pancreatic disease virus (SPDV), 1384
Salmon River tick fever virus, 841
Salmon Island virus, 1268
Salvieja virus, 1269
Salyk virus, 388–389
Seiure
enterovirus-related, 1125
HHV-5, 515
HHV-7-related, 515
rotavirus-related, 864
Selectiv e serotonin reuptake inhibitors (SSRIs), prion disease, 1439
Self proteins, 333
Semliki Forest virus (SFFV), 1347–1351, 1353, 1355, 1374
Sendai virus, 332, 874
Seoul virus, 142, 1066, 1068, 1071
Seoul virus vaccine, 1072
Sepik virus, 1269, 1281
Sepsis, enterovirus-related, 1125–1126
Serodiagnosis, 306
antibody response to viral infections, 307–308
complement fixation, 309
detection of viral antibodies, 309
hemagglutination inhibition, 309
IgM antibody determination, 312
immune adherence hemagglutination assay, 310
immunoblot, 311
immunohematologic assay, 311–312
immunofluorescence assay, 310
interpretation of test results, 312–313
neutralization assay, 309–310
passive latex agglutination, 311
solid-phase immunosassay, 310–311
specimens, 308–309
Serum, testing for viral antibodies, 308–309
Seron, testing for viral antibodies, 308–309
Seron sickness, HBV, 731
SERSV. See Southern elephant seal virus
Severe acute respiratory syndrome coronavirus (SARS-CoV)
animal reservoir, 1245
biology, 1245–1248
cell culture, 1247
classification and taxonomy, 1243–1244
clinical manifestations, 1254–1255
diagnosis, 291, 305
distribution and geography, 1248
experimental animal models, 1247
gastroenteritis, 53
genome, 1245–1246
historical aspects, 1243
host range, 1247
Severe acute respiratory syndrome coronavirus (SARS-CoV) (continued)
immune response, 330, 1253
inactivation by physical and chemical agents, 1248
incidence and prevalence of infection, 1249
laboratory diagnosis, 1255–1256
nosocomial infections, 1251
pathogenesis, 1252–1253
pneumonia, 20
prevention, 1256–1257
replication, 1252
risk factors, 1252
serodiagnosis, 1256
transmission, 1250–1251
treatment, 1257
Severe acute respiratory syndrome coronavirus (SARS-CoV) vaccine, 1256–1257
Severe fever with thrombocytopenia syndrome (SFTS), 141–143, 1059–1060, 1063, 1076–1077
Sewage, workers exposed to, 1178
Sexual transmission
adenovirus, 588
CMV, 489
EBV, 529
HAV, 1177
HBV, 722, 734
HCV, 1322–1323, 1329
HDV, 1414
hepatitis viruses, 62, 64–65
HIV, 131, 804, 818–819
HPV, 117–118, 637–638
HSV, 422
HTLV, 777, 786–787
KHSV, 557, 564
molluscum contagiosum virus, 398
SFTS. See Severe fever with thrombocytopenia syndrome
SVF. See Semliki Forest virus
Sheep
bornavirus, 1397
tick-borne encephalitis virus, 1285–1286
Shell vial culture, 294
Shingles. See Herpes zoster
Ship fever, 874
Shokwe virus, 1060
Sicca syndrome, HCV, 1327
Sifiverticlide, 172
Silicium, for KHSV, 565
Silver nitrate stick, for HPV infections, 657, 659–660
Simprevir, 246, 1332–1333
adverse effects, 254
clinical applications, 254
for HCV, 131
pharmacology, 254
resistance, 254
spectrum of activity, 253–254
structure, 251
Simian immunodeficiency virus (SIV), 334, 795–796
Simian rotavirus, 842
Simian T-cell lymphotropic virus, 771–772, 774
Simian virus 5, 874
Simian virus 40 (SV40)
animal models, 607–608
attachment and entry into cells, 602–603
biology, 602–606
carcinogenesis, 612–613
cell culture, 603, 605
cell transformation, 605
classification and taxonomy, 599–600
epidemiology, 606–607
historical aspects, 599
host range, 1249
as human agent, 606
immunocompromised individual, 600
interaction with glial cell cultures, 603, 605
pathogenesis, 600, 607
proteins, 601–603
replication, 603, 608
sites of infection, 600
transmission, 606–607
viroton structure and composition, 599–601
Sindbis virus (SINV), 1370–1371
classification, 1347
clinical manifestations, 1348, 1371
CNS infections, 1348
epidemiology, 1371
laboratory diagnosis, 1355, 1371
pathogenesis, 1354–1355
prevention, 1377
replication, 1351, 1353
skin lesions, 1371
subtypes, 1348
transmission, 1348
treatment, 1371
viroton composition, 1351
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
Sin Nombre virus, 3
Sixth disease.
for HCV, 131
mechanism of action, 249
pharmacology, 250
resistance, 250–251
spectrum of activity, 249
structure, 250
Solid organ transplantation (SOT), 75. See also Transplant recipient
Solid-phase immunoassay, 298–299
serodiagnosis, 310–311
Somatic hypermutation, antibodies, 342
Somaticoform disorder, chronic fatigue syndrome and, 375
Sosuga virus (SosPV)
animal reservoirs, 950, 955–956
antigen detection, 959
biology, 953
classification and taxonomy, 949
clinical manifestations, 950, 958–959
distribution and geography, 955
epidemiology, 955–956
genome, 949–951
laboratory diagnosis, 959
prevention, 959–960
proteins, 951–953
receptors, 953
transmission, 955–956
treatment, 960
virology, 949–953
SOT. See Solid organ transplantation
Southern elephant seal virus (SESV), 1347, 1349
Soyaprevir, 247, 1333
SPDV.
Spondweni virus, 1269, 1281
Splenic rupture, infectious mononucleosis, 625, 639
Sperm donation, CMV transmission, 489
Specimens
Specific immunity. See Adaptive immunity
Specimens
diagnostic virology, 291–292
extraction of nucleic acids, 301
serodiagnosis, 308–309
Sperm donation, CMV transmission, 489
Splenic rupture, infectious mononucleosis, 533–534
Spondweni virus, 1269, 1281
Spumavirus, 3
Squamous cell carcinoma, HPV, 118–119, 623, 639–640, 648–649
Squamous cell papilloma, oral, 648
Squamous intraepithelial neoplasia, 625, 648–649
Squarc acid dibutyl ester, for warts, 660
Squamous intraepithelial neoplasia, 625, 648–649
Squarcid acid dibutyl ester, for warts, 660
Squirrels, bornavirus, 1396–1397
SRSVs. See Small round structured viruses
dsDNA viruses, taxonomy, 2
SSRIs. See Selective serotonin reuptake inhibitors
ssRNA viruses, taxonomy, 3–4
Stevens-Johnson syndrome, 1030
STL polyomavirus, 600, 614
Strand displacement amplification, 303
Stratford virus, 1268
Striobil, 197
Strip immunoblot assays, 311
Stroke, varicella-related, 468
Stromal keratitis, HSV, 156
Strongyloidiasis, HTLV, 783, 785
Subacute sclerosing panencephalitis, 916–917
Subviral agents, taxonomy, 4
Super E-Mix, 294
SV40. See Simian virus 40
Swollen head syndrome, 874
Syncytia, HIV, 803, 809
T
T-705, for influenza virus infections, 1042
TAC. See Transient aplastic crisis
Taca virus, 1060
Tara virus, 1099–1090, 1097
Tacrolimus, for hepatitis E infections, 1220
Tahyna virus, 1060, 1063
Tanapox virus (TANV) classification and taxonomy, 388
clinical diagnosis, 405
clinical manifestations, 388, 402–403
epidemiology, 388, 395, 397
pathogenesis, 400
structure, 389
TagMan process, 302
Tat protein, HIV, 798–799, 802
Taunton virus, 48, 1190
Taxonomy of viruses, 1–4
Tax protein, HTLV, 772–774, 778–779
TBE-Moscow, 1287
TBEV. See Tick-borne encephalitis virus
T-cell lymphoma, EBV, 537
T-cell receptor (TCR), 332–333, 336–337
T cells, 325, 332–334
antigen recognition, 336–340
CD4+
antigen recognition, 336–337
cytolytic, 340
differentiation, 337–340
helper, 338
HIV-infected, 802–803, 805–810
immunologic basis of vaccination, 357–358
triggering of, 333–334
CD8+
antigen recognition, 336–337
cytotoxic, 338
differentiation, 337–338
EBV, 531–532
effector subsets, 338–340
helper, 338–339
HIV, 810
HTLV. See Human T-cell lymphotropic virus
negative selection, 333
positive selection, 333
Tfh, 339
Th1, 339
Th2 and Th9, 339
Th17, 339
Tregs, 339–340
TCR. See T-cell receptor
TD-6450, 247
Tecovirimat
for poxvirus infections, 407–408
for vaccinia virus, 162
Tegument, CMV, 481
Telaprevir, 1333
Telbivudine
adverse effects, 240, 243
clinical applications, 243
dosing regimen, 240
for HBV, 242–243, 736, 739–740
mechanism of action, 242
pharmacology, 243
resistance, 243, 739, 742
spectrum of activity, 242
structure, 241
Tembusu virus, 1269
Tenforovir alafenamide
adverse effects, 176, 184
clinical applications, 170, 184
dosing regimen, 240
drug interactions, 176, 184
fixed-dose combination, 197
for HIV, 170, 176, 178, 184
mechanism of action, 184
pharmacokinetics, 176
pharmacology, 184
resistance, 184
structure, 178
Tenforovir disoproxil fumarate
adverse effects, 176, 183, 240
clinical applications, 170, 183–184
dosing regimen, 170, 240
drug interactions, 176, 183
fixed-dose combination, 197
for HBV, 62, 70, 243, 736, 740–741
for HIV, 170, 176, 178, 183–184
postexposure prophylaxis, 819
preexposure prophylaxis, 818–819
mechanism of action, 183
pharmacokinetics, 176
pharmacology, 183
resistance, 183
structure, 178, 241
Tetravalbivirus (PARV4), 679–684, 686, 690
T follicular helper cells, 339
TGEV. See Transmissible gastroenteritis virus
Th1 cells, 339
Th2 cells, 339
Th9 cells, 339
Th17 cells, 339
Therapeutic drug monitoring, CMV treatment, 504
Thimerosal, 361
Thiosemicarbazone, for poxvirus infections, 407
Thogoto virus, 1009, 1030
Thrombocytopenia
HIV, 813
measles virus, 918
Thrombocytopenic purpura, rubella virus, 1387, 1389
Thymosin-α-1, for HBV, 747
Thyroid disease, HCV, 1327
Tick-borne disease
alphavirus, 1353
arthropod-borne reovirus. See Reovirus bunyavirus, 1063
CNS infections, 33–34
Colorado tick fever virus. See Colorado tick fever virus
Crimean-Congo hemorrhagic fever virus, 1077
flavivirus, 1267–1268, 1271–1273, 1281
hemorrhagic fever viruses, 142–143
Kyasanur Forest disease virus, 1302
Omsk hemorrhagic fever virus, 1302
prevention of tick bites, 847
severe fever with thrombocytopenia syndrome, 1076
Tick-borne encephalitis virus (TBEV), 1268, 1275, 1284–1287
Tick-borne encephalitis virus vaccine, 1287
Tofamivir
adverse effects, 194, 197
clinical applications, 170, 198
cutaneous adverse effects, 134
Tipranavir (continued)
dosing regimen, 170
drug interactions, 194, 197–198
for HIV, 170, 194, 196–198
pharmacokinetics, 194
pharmacology, 197
resistance, 198
structure, 196
Tissue-specific self-antigens (TSAs), 333
TLRs. See Toll-like receptor
TMC647055, 247
Togavirus, taxonomy, 4
Toll-like receptors (TLRs). See TLRs
Tissue-specific self-antigens (TSAs), 333
Tonate virus, 1348, 1355
Tonsillitis, adenovirus, 585–588
Topotecan, for PML, 615
Toronto agent, 48
Toxorvirus, 48, 53, 1244–1245
Torrone teno virus (TTV)
classification and taxonomy, 2, 701–702
clinical manifestations, 706–707
epidemiology
distribution and geography, 705
transmission, 705–706
historical aspects, 701
laboratory diagnosis, 707
pathogenesis
disease associations, 706–707
immune response, 706
pathology, 706
prevention, 707
treatment, 707
virology
composition, 703–705
discovery, 701
genetic variability, 702–703
replication, 705
Toscana virus, 1060
Tosrovirus, 1059
Towne vaccine, 498
Toxic shock syndrome, influenza virus, 1030
Tracheitis, 13, 18
Tracheobronchitis
clinical features and syndrome definition, 18
etiology, 10, 18
measles virus, 914, 916
treatment and prevention, 18
Transient aplastic crisis (TAC), parvovirus
B19, 683–687, 690
Transmissible gastroenteritis virus (TGEV), 1243, 1247
Transmissible spongiform encephalopathy (TSE)
antimal models, 1426
antigen detection, 1436
brain MRI, 1435–1436
cerebrospinal fluid analysis, 1434–1435
clinical manifestations, 1426,
1431–1434
CNS infections, 39–42
complications, 1434
diagnosis, 1434–1436
differential diagnosis, 1437
EEG, 1434
epidemiology, 1428–1430
geneic testing, 1436
historical aspects, 1425–1426
passive immunoprophylaxis, 1439
pathogenesis, 1430–1431
prevention, 1437–1439
prion biology, 1427–1431
protein-only hypothesis, 1426
specimen collection and handling, 1439
treatment, 1439
Transplant recipient
adenovirus, 76, 575, 583, 587–588, 590
BK virus, 75, 87–88, 607, 610–612,
614–616
CMV, 491–494
cellular immunotherapy, 82
clinical manifestations, 78
drug resistance, 81–82
epidemiology, 75–76
immune monitoring, 77–78
pathogenesis, 76–77
prevention and treatment, 78–82,
498–503
primary infection transmission, 489
risk factors, 76
seronegative recipient, 78
vaccination, 82
coronavirus, 1234
EbV, 75–76
cellular immunotherapy, 85
clinical manifestations, 84
epidemiology, 82–83
humoral immunotherapy, 85
immune monitoring, 84
pathogenesis, 82–83
posttransplant lymphoproliferative
disorder, 535–536
risk factors, 83–84
treatment, 84–85
HBV, 722
HCV, 1327–1328
hepatitis in, 71, 75–76
HEV, 1216, 1220–1221
HHV-6, 75–76, 85–86, 515
HHV-7, 85–86, 515
HPV, 638–640
HIV, 76, 87, 430
HTLV, 75
infection onset in, 75–76
influenza virus, 1027, 1029, 1034
JC virus, 88
KSHV, 75–76, 86–87, 558, 564
parainfluenza virus, 884
PML in. See Progressive multifocal
everal encephalopathy
polyomavirus, 75–76, 87–88, 606–616
rabies virus, 968–969
respiratory viruses in, 75
RSV, 884
VZV, 76, 87, 464, 468
Transport, specimens, 291–292
Transverse myelitis
influenza virus, 1030
VZV, 468, 470
Travel-related illness
gastroenteritis, 52, 54
HAV, 1177, 1182–1183
hepatitis, 63, 67
HEV, 1209, 1212
yellow fever virus, 1301
Tregs. See Regulatory T cells
Tretinoin cream, for HPV infections,
Trichophyton rubrum, for VZV infections,
Tricyclic phenothiazine compounds, prion
disease, 1439
Triflurouromidine, for HSV infections, 157
Trifluridine, 215
adverse effects, 219, 223
clinical applications, 217, 223
dosing regimen, 217
drug interactions, 219, 223
for herpesvirus infections, 216–219, 223
for HSV infections, 217, 223
mechanism of action, 223
pharmacokinetics, 219, 223
resistance, 223
spectrum of activity, 223
structure, 216
for vaccinia virus, 407
for VZV infections, 223
Trigeminal neuralgia, postherpetic, 420
Triment, 197
Triclosan, 1348
Truvira, 196
Truvirone, 259
TSAs. See Tissue-specific self-antigens
TSE. See Transmissible spongiform
everal encephalopathy
TTMDV. See TTV-like midivirus
TTMV. See TTV-like minivirus
TTV. See Torque teno virus
TTV-like midivirus (TTMDV), 701–707
TTV-like minivirus (TTMV), 701–707
Tuberculosis
HIV and, 813
measles virus and, 918
Turkey rhinotracheitis virus, 874
Tussavirus (TuV), 679–683, 686, 688–689
Twinrix, 353, 359, 1181–1183
Type 1 diabetes mellitus, enterovirus and,
1129–1130
Tuvelyni virus, 1268
Tzanck smear, 116, 121–122, 299, 471
U
Uganda S virus, 1269
Una virus (UNAV), 1348, 1353, 1374
Urethritis, adenovirus, 587
Urinary tract disease, BK virus, 87–88, 607
clinical manifestations, 614
immune response, 613
laboratory diagnosis, 615
pathogenesis, 610–612
prevention and treatment, 615–616
virological features, 611–612
Urine
CMV detection, 495
testing for viral antibodies, 309
Usuru virus, 1268, 1281
Uveitis
common viral pathogens, 153–154
HTLV, 162, 782–783, 785
immune-recovery, 155
V
V-787, for influenza pneumonia, 1042
Vaccine
active immunization, 351
adenovirus, 353, 360, 575, 589–590
adjuvants, 358–359
adverse effects
allergic reactions, 363
expected, 362–363
rare or idiosyncratic events, 363–364
reporting events, 364
Varicella-zoster virus (VZV), 2
Varicella (immunocompromised individual), historical aspects, 459
hepatitis, 70
genome, 460
ganciclovir for, 223
antivirus agents for. See Antiviruses against
antiviral resistance, 475
antiviral susceptibility testing, 295–296
biology, 461–463
brivudine for, 222–223
cell culture, 292–294, 471
cell-to-cell spread, 461–463
chronic fatigue syndrome, 372
classification and taxonomy, 459–460
clinical manifestations, 300, 467–470
CNS complications, 468, 470
CNS infections, 32, 36, 38, 42
genital infection, 163
cytomegalovirus, 299–300
diagnosis, 116, 291
distribution and geography, 463
drug prophylaxis, 474–475
encephalitis, 468, 470
treatment for, 474–475
foscarnet for, 87, 218, 226–227, 474–475
ganciclovir for, 223–225
virologists, 460
granulomatous angiitis, 470
hepatitis, 70
historical aspects, 459
HIV–VZV coinfection, 132, 468–470
472–473
immune response, 466–467
immunassay, 297–298
immunocompromised individual, 463–464, 467–472
incidence and prevalence of infection, 463–464
incubation period, 465–466
laboratory diagnosis, 471
latency, 462–464, 466–467
meningitis, 468–469
mortality from, 464
myocarditis, 100
neonatal infections, 463, 467, 472
neurovirulence, 972
nosocomial infection, 463–464
ocular manifestations, 153–155, 157–159, 163
pathogenesis, 465–467
PCR methods, 471
penciclovir for, 221–222
pneumonia, 10, 19, 21–23, 464, 468–469
in pregnancy, 464, 470, 472
prevention, 471–475
protein, 460–461
reactivation. See Herpes zoster
replication, 460, 465–466
retinitis, 470
seasonality, 9, 463
serodiagnosis, 307–308, 312, 471
skin lesions, 115–116, 464–469
diagnosis, 123
epidemiology and clinical manifestations, 122–123
treatment and prevention, 124
transmission, 464–465
transplant recipient, 76, 87, 464, 468
transverse myelitis, 468, 470
treatment, 474–475
trifluridine for, 223
valacyclovir for, 124, 159, 221, 474–475
virology, 459–463
Varicella-zoster virus (VZV) vaccine, 122,
Varicella-zoster virus (VZV). See Also Smallpox
classification and taxonomy, 2, 387–388
clinical diagnosis, 405
clinical manifestations, 388, 401–403
epidemiology, 388, 395–397
genome, 388
historical aspects, 387
host range, 388, 394
immune response, 401
laboratory diagnosis, 405
pathogenesis, 398–400
prevention, 406–407
skin lesions, 119–120
structure, 389
transmission, 397–398
treatment, 407–408
Varivax, 124, 354
VaryZIG, 471–472
VARD. See Varicella virus
Vasculitis, Nipah virus, 957–958, 960
Vasopressin, for myocarditis-related heart failure, 107
Vasopressors, for myocarditis-related heart failure, 107
vCJD. See Variant Creutzfeldt-Jakob disease
vCyclin, KSHV, 561
VDPV. See Vaccine-derived PV
Vedraprevir, 256, 1333
VEEV. See Venezuelan equine encephalitis virus
Velpatasvir, 246, 252, 260–261, 1333
Venezuelan equine encephalitis virus (VEEV) vaccine, 1366
Ventriculography, myocarditis, 103
Verdineo, 283
Veregen, for HPV infections, 658, 660
Verruca plana, 118, 646
Verruca vulgaris, 118, 646
Verrucous carcinoma, 648
Vesicular stomatitis virus, 3, 967–968, 970–971
vaccine, 359
Vesiculovirus, 967–968, 970–973, 976
vFLIP, KSHV, 561–562
VICT. See Vaccine Injury Compensation
Program
Vidarabine, 215
for HSV infections, 437
VIF protein, HIV, 799–800, 802
Viblanstine, for Kaposi’s sarcoma, 564
Viral transport medium (VTM), 292
Virotheme, HIV alterations in, 324
ViroSeq HIV-1, 296
Viromes, 360
VISO. See Vaccine Information Statement
VISON, 285
Vitamin A, for measles virus infections, 923
Vitamin C, for common cold, 1157
Vitamin K, for arenavirus infection, 1104
for filovirus infection, 1000
Vireumus, for testing viral antibodies, 309
VP protein, HIV, 799–800, 802
Vpu protein, HIV, 799–800, 802
Vpx protein, HIV, 799–800
VRCDI, 175
VSBV-1. See Variegated squirrel bornavirus 1
VST. See Varicella-zoster immune globulin
VZV. See Varicella-zoster virus

W
Warts
HPV
clinical manifestations, 464
histology, 643–644
incidence and prevalence, 637
prevention, 651, 653
risk factors, 638
spontaneous regression, 644
treatment, 643–641
treatment, 657–663
immune system defects, 323
Wasting syndrome, HIV, 812–813
Waterbird 1 bornavirus, 1396
Waterborne hepatitis, 62–64
WEEV. See Western equine encephalitis virus
Weselbron virus, 1269, 1281
Western blot, 311
prion protein, 1435–1436
Western equine encephalitis virus (WEEV)
classification, 1347, 1360
clinical manifestations, 1348, 1361–1362
CNS infections, 33–34, 40
complications, 1362
differential diagnosis, 1362
distribution and geography, 1348, 1360
epidemic patterns, 1361
epidemiology, 1360–1361
genotypes, 1347–1349
host range, 1353, 1360
incidence and prevalence of infection, 1360–1361
incubation period, 1361
laboratory abnormalities, 1362
laboratory diagnosis, 1355, 1362
outcomes, 1362
pathogenesis, 1354
pathology, 1361
prevention, 1356, 1362
risk factors, 1361
subtypes, 1348
taxonomy, 4, 1350
transmission, 1348, 1361
treatment, 1362
virology, 1360
West Nile fever, 1289
West Nile virus (WNV), 1267–1268
arthropod vectors, 1272
biology, 1287–1288
cell culture, 1272
chronic fatigue syndrome, 372
clinical manifestations, 1289–1290
CNS infections, 31, 33–34, 38
diagnosis, 1290
distribution and geography, 1288
epidemiology, 1288–1289
host range, 1272
immune response, 343, 1274
incidence and prevalence of infection, 1288–1289
pathogenesis, 1273–1274, 1289
in pregnancy, 1289
prevention, 1290–1291
risk factors, 1289
serodiagnosis, 307, 310, 312
transmission, 1273, 1289
treatment, 1290

West Nile virus (WNV) vaccine, 1290–1291
Whataroa virus, 1348
Whitewater Arroyo virus, 141, 1089–1090, 1097
Whitlow, herpetic, 121–122, 430, 436
Whooping cranes, eastern equine encephalitis virus, 1357
WNV. See West Nile virus
Woodchuck HBV, 722
WU virus, 599–600, 606, 614

X
Xenotransplantation, 4
Xenotropic murine leukemia virus-related virus (XMRV), 374
Xing virus, 1060
X-linked lymphoproliferative syndrome (XLP), EBV, 534–535
XMRV. See Xenotropic murine leukemia virus-related virus
Xylometazoline, for common cold, 1157

Y
Yaba monkey tumor virus (YMTV)
classification and taxonomy, 2, 388
clinical diagnosis, 405
clinical manifestations, 388, 403
epidemiology, 388, 397
host range, 388
pathogenesis, 400
structure, 389
Yaounde virus, 1268
Yellow fever virus (YFV), 141, 849, 1267, 1269
arthropod vectors, 1272
barrier immunity, 323
biology, 1298–1299
cell culture, 1272
chronic fatigue syndrome, 372
clinical manifestations, 145–146, 1300
diagnosis, 1300–1301
distribution and geography, 1299
epidemiology, 142–143, 1299
hepatitis, 1299–1300
host range, 1272–1273
immune response, 1300
incidence of infection, 1299
pathogenesis, 144, 1273–1274, 1299–1300
prevention, 1300–1301
serodiagnosis, 307
taxonomy, 4
transmission, 1299
treatment, 1301
treatment, 1302
virus-specific factors in virulence, 1275
Yellow fever virus (YFV) vaccine, 148, 354, 364, 1301
YFV. See Yellow fever virus
YF-Vax, 354
YMTV. See Yaba monkey tumor virus
Yokose virus, 1269
Yunnan orbivirus, 842

Z
Zanamivir
adverse effects, 276, 278
clinical applications, 275, 278–279
dosing regimen, 274
drug interactions, 276, 278
effectiveness of, 1039
for influenza, 272, 274–279, 1039, 1041
mechanism of action, 278
pharmacokinetics, 276, 278
for pneumonia, 22–23
resistance, 278, 1041
spectrum of activity, 278
structure, 272, 277–278
susceptibility testing, 295–296
Zidovudine (AZT), 795
for adult T-cell lymphoma, 786
adverse effects, 176, 179
clinical applications, 170, 179–180
dosing regimen, 170
drug interactions, 176, 179
perinatal administration, 820
for HTLV-associated myelopathy, 787
for KSHV, 565
mechanism of action, 178
pharmacokinetics, 176
pharmacology, 178–179
resistance, 179
structure, 178
Zika virus, 1269, 1298
Zinc
for common cold, 12, 1157
for gastroenteritis, 54
for rotavirus infections, 866
ZMapp, for filovirus infection, 1000
Zoonosis
hepatitis, 63
influenza virus. See Influenza virus
paramyxovirus, 949–953, 956
poxvirus, 387
Zostavax, 124, 354, 473
Zoster. See Herpes zoster
Zoster sine herpete, 469